Utilizing Antigenic Peptide and Adhesion Molecule Conjugates to Suppress Autoimmune Disease in Animal Models by Buyuktimkin, Barlas
 
UTILIZING ANTIGENIC PEPTIDE AND ADHESION MOLECULE 
CONJUGATES TO SUPPRESS AUTOIMMUNE DISEASE IN ANIMAL 
MODELS 
By 
Barlas Büyüktimkin 
Pharm.D., Pharmacy, The University of Kansas, 2005 
M.S., Pharmaceutical Chemistry, The University of Kansas, 2008 
 
Submitted to the Department of Pharmaceutical Chemistry and the Faculty of the 
Graduate School of the University of Kansas in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy. 
 
                                             Dissertation Committee:   
       
________________________________        
    Chairperson                Teruna J. Siahaan       
________________________________        
Cory J. Berkland 
________________________________        
Jennifer S. Laurence 
________________________________        
David B. Volkin 
________________________________  
Krzysztof Kuczera 
  
 
Date Defended: October 7, 2011 
 ii 
 
The Dissertation Committee for Barlas Büyüktimkin 
certifies that this is the approved version of the following dissertation: 
 
 
Utilizing Antigenic Peptide and Adhesion Molecule Conjugates to Suppress 
Autoimmune Disease in Animal Models 
 
 
                        Dissertation Committee:   
       
________________________________        
    Chairperson                Teruna J. Siahaan       
________________________________        
Cory J. Berkland 
________________________________        
Jennifer S. Laurence 
________________________________        
David B. Volkin 
________________________________  
Krzysztof Kuczera 
 
  
 
       
 
 
Date approved: October 7, 2011 
 iii 
Utilizing antigenic peptide and adhesion molecule conjugates to suppress 
autoimmune disease in animal models 
 
Barlas Büyüktimkin 
The University of Kansas, 2011 
 
Peptides and proteins have been used as carriers to target and deliver molecules to 
sites of action. Conjugating a drug to a macromolecule offers the unique advantage of 
being able to target drug to a specific cell surface receptor with high affinity, thereby 
increasing efficacy and reducing side effects. Furthermore, conjugations between two 
different peptides, or between peptide and protein, that have activities to modulate two 
receptors have shown promising results in suppressing autoimmune diseases in animal 
models. Therefore, the objective of the dissertation was to explore the possibility of 
selectively targeting peptide and protein conjugates to antigen presenting cells to 
suppress autoimmune diseases. The I-domain of leukocyte function associated antigen-1 
(LFA-1) conjugated to antigenic PLP139-151 peptide (IDAC-3) suppressed experimental 
autoimmune encephalomyelitis (EAE) when delivered in a vaccine-like manner by 
shifting the immune balance away from Th17-mediated pathology by increasing 
involvement of T-reg cells (Chapter 2). PLP139-151 conjugated to LABL adhesion peptide 
(Ac-PLP-BPI-NH2-2) was formulated in a colloidal gel for a one-time subcutaneous 
administration to suppress EAE. A vaccine-like administration of the peptide conjugate 
suppressed EAE as well as the relapse. In vitro cytokine studies suggested that the 
mechanism of suppression was due to the shift of the immune balance away from a Th17-
 iv 
mediated response (Chapter 3). The utility of BPI to target other autoimmune diseases 
such as collagen-induced arthritis (CIA) was also investigated. Here, collagen type II 
peptides were conjugated to LABL (CII-BPI). It was found that suppression of disease is 
dependent upon the sequence of the antigen, and that the mechanism of disease 
suppression was linked to a shift in the immune balance from a proinflammatory to a 
regulatory response (Chapter 4).  
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CHAPTER 1 
Development of therapeutic macromolecule conjugates to make better drugs 
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1.1 INTRODUCTION 
Roche Chief Executive Officer Severin Schwan noted that the next generation of 
drugs to be developed must target specific groups of patients: 
 
“In 10 years we would see half of our portfolio be targeted therapies. And if 
anything, I would assume in 20 years this percentage is going to increase.” 
 
The current state of modern medicine is such that our understandings of the 
physiology of a human body and its complexities have grown exponentially. This 
dramatic growth in knowledge has allowed scientists to better understand and pinpoint 
the intricate differences between normally functioning cells and “diseased” cells. The 
differences between these cells could be due to cell-surface receptor changes, shifts in 
cytokine and hormone production, and differences in cell trafficking properties.1-5 
Targeted therapy utilizes these differences to guide the drug to a site of action on the 
diseased cell for its greatest impact.4,6,7  
Peptides and proteins (e.g., antibodies) have been used as carrier and targeting 
molecules. The rationale for developing conjugates is to combine the specificity of the 
carrier (i.e., proteins or peptides) with the efficacy of the attached drug molecule. 
Currently, there are over 200 marketed protein products; however, the rate of approval of 
protein drugs has slowed down over the last five years.8  Of the protein drugs in the 
market, 24 are antibodies.8 Recently, more effort has been devoted to developing protein-
drug conjugates (i.e., antibody-small drug and antibody-peptide conjugates (peptibodies)) 
and peptide-drug conjugates (Fig. 1).8 However, the 
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Figure 1. Structure of an antibody-drug conjugate (ADC). 
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development of these conjugates has been relatively slow; this is due to the lack of prior 
knowledge in developing these types of therapeutics. The major advantage of using a 
monoclonal antibody (mAb) for targeting drugs to a specific cell is that it has the ability 
to target a specific antigen on the cell surface with high binding affinity.  
Understanding the physiological processes of diseases is an important step in 
developing macromolecule-drug conjugates. However, numerous other challenges need 
to be addressed before macromolecule-drug conjugates become candidates as 
therapeutics. An ideal conjugate should have the same binding properties to the target 
receptor in the cell surface as the parent macromolecule. Furthermore, the formation of 
conjugate should not impair or limit its biodistribution in vivo, and the drugs should not 
be released from the conjugate prior to reaching the target site. Once it is at the target site, 
and if the drug action is inside the cell, the conjugate should be internalized and the drug 
molecules should efficiently be released in their active form. A sufficient amount of drug 
must reach the site of action to produce optimal efficacy.  
The aim of this chapter is to provide a review on the current state of development 
of the macromolecule-drug conjugate technology in improving drug delivery to a specific 
tissue or cell type. Ultimately, the hope is that macromolecule-drug conjugates should 
have greater efficacy than the parent drugs with a better safety profile.  
 
1.2 ANTIBODY-DRUG CONJUGATES (ADC) 
1.2.1 Success of ADC in the Market 
The role of the antibody in antibody-drug conjugates (ADC) is to target the drug 
(cargo molecule) to an identified site, thereby reducing toxicity and increasing 
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effectiveness. The ideal characteristic of ADC is that the antibody has high specificity to 
the target molecule on the surface of target cells where the receptors are upregulated. 
Then, the drug molecules should be released at the appropriate site in the cell. Several 
ADC have been approved for treating patients. The first FDA-approved ADC was 
gentuzumab ozogamicin (Mylotarg®); this ADC was used for the treatment of acute 
myeloid leukemia (AML).9,10 The antibody in Mylotarg targets the CD33 molecule, 
which is highly expressed in ~90% of malignant blast cells in AML.11 Ideally, an ADC 
should not be a substrate for efflux pumps; unfortunately, Mylotarg has a DNA-binding 
calicheamicin derivative, which is a substrate for the MDR1/P-gp-1 efflux pump.12 In 
2010, Mylotarg was withdrawn from the market due to unsatisfactory patient benefit and 
increased patient death in post-approval clinical trials (SWOG S0106). Brentuximab 
vedotin (Adcetris®) was granted an accelerated approval in August 2011 for the treatment 
of systemic anaplastic large cell lymphoma (ALCL) and Hodgkin’s lymphoma (HL). It is 
the first HL drug to receive FDA approval since 1977. Adcetris targets the drug to 
lymphoma cells via binding to CD30 molecules.13 Another ADC, trastuzumab emtansine, 
is in clinical trials for treating metastatic breast cancer (HER/neu+). This ADC is a 
conjugate of trastuzumab (Herceptin®) mAb that targets Her2/neu receptor (CD340) and 
cytotoxic mertansine (DM1).14 
 
1.2.2 Examples of Cargo Molecules  
Chemotherapeutic ADC should be more effective than the free cargo drug alone 
because the cost to produce antibodies is high and there are limited conjugation sites on 
the mAb for the cargo molecules. There are several potent anticancer drugs used for 
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cargoes of ADC; they include DNA damaging agents (i.e., calicheamicin and 
duocarmycin) and microtubule inhibitors (i.e., auristatins, taxanes, and maytansinoids). 
These anticancer agents have nonspecific toxicity; therefore, conjugating them to mAb 
provides specificity for cancer cells and avoids side effects. Peptide sequences of 
diphtheria toxin have been fused with interleukin-2 (IL-2) to make denileukin diftitox 
(Ontak®), an approved drug for the treatment of cutaneous T-cell lymphoma (CTCL).4 
Other toxins such as ricin, RNAse, and Pseudomonas exotoxin have been conjugated to 
monoclonal antibodies and are being investigated for cancer treatments.15-17 
Radiolabeled atoms (i.e., 131I, 90Y, and 177Lu) have been conjugated to mAbs for 
use in radiotherapy in cancer patients. For example, 131I-tositumomab (Bexar®) and 90Y-
ibritumomab tiuxetan (Zevalin®) are both FDA-approved ADCs that target CD20 on the 
cancer cells of non-Hodgkin’s lymphoma (NHL).18 Currently, 90Y-epratuzumab teraxetan, 
which is specific for CD22-expressing cancer cells, is in development.19 
 
1.3 CHEMISTRY OF ADC 
1.3.1 Cleavable Linkers 
1.3.1.1 Acidic Linkers 
Acid-sensitive cleavable linkers have been used to conjugate drugs to mAbs 
because the desire is to release the drug inside the lysosomes in an acidic pH environment. 
The hydrazone linker is relatively stable in blood (pH ~7.4), but it cleaves in acidic 
endosomes (pH 5.0 – 6.5) and lysosomes (pH 4.5 – 5.0), as well as in the more acidic 
environment inside cancer cell. An early example was doxorubicin conjugated to the 
cysteine residue of BR96 mAb via a combination of maleimide and hydrazone linkers  
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(Fig. 2).7 BR96 binds to the Lewis Y receptor that is overexpressed on many 
carcinomas.7,20 The thiol group of the cysteine residue of BR96 mAb was conjugated to a 
maleimide-hexanoic acid linker, and the carboxylic acid group of maleimide-hexanoic 
acid was coupled to the hydrazone group of hydrazone-derivatized doxorubicin to make 
the final BR96-Dox-ADC.  
It was found that BR96-Dox-ADC had better antitumor efficacy than free 
doxorubicin. To achieve the same efficacy as that of doxorubicin, BR96-Dox-ADC was 
delivered at a dose equivalent to 13% of free doxorubicin.7 This suggests that the 
antibody preferentially targets and carries the doxorubicin to the Lewis-Y-expressing 
tumor cell. It was suggested that, once inside the acidic tumor cell environment, 
doxorubicin is clipped off via hydrolysis of the hydrazone.21   
 
1.3.1.2 Reducing Linkers 
The cytotoxic drugs (i.e., calicheamicin class) in Mylotarg and inotuzumab 
ozogamizin were covalently linked to lysine residues of anti-CD33 IgG4 antibody via a 
combination of hydrazone and disulfide bond (Fig. 3). It was found that the drug was 
released from the ADC in lysosomes via acid hydrolysis of the hydrazone functional 
group. Finally, the drug was activated upon reduction of the disulfide bond.21 One 
interesting aspect of the disulfide linker is that the sulfur atom of the thiol group is linked 
to a carbon with a gem-dimethyl group. The steric hindrance from the gem-dimethyl 
group slows the reduction of the disulfide bond by glutathione in plasma (Fig. 3). Upon 
entry into the cell, the disulfide bond can be released more rapidly than in plasma 
 8 
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Figure 2. Structure of Br96-Dox-ADC immunconjugate. A cysteine residue of BR96 
mAb forms a thioether bond with maleimide. The acid-labile hydrazone forms a linker 
between maleimide-hexanoic acid and doxorubicin. 
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Figure 3. Cytotoxic calicheamicin (Cal) cargo is attached to an anti-CD33 antibody 
via a hydrazone linker. The disulfide bond is stabilized by two geminal methyl groups 
to prevent calicheamicin release prior to reaching its target. 
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because the concentration of glutathione is a thousand times higher in the cytoplasm of 
tumor cells than in the plasma.22 
A similar concept using a steric disulfide bond conjugation was used in 
maytansinoids, where DM1 or DM4 drug was conjugated to mAbs via the lysine residues 
(Fig. 4). The amino group of surface lysine residues was conjugated to 4-thiolbutanoate 
via a peptide bond. The thiol group on mAb was conjugated to DM1 or DM4 drug via a 
disulfide bond.  In this case, the gem-dimethyl group is on the DM4 drug molecule but 
not in the DM1 drug molecule. The DM4-ADC has a longer half-life (102 hours) 
compared DM1-ADC (47 hours); this is due to the presence of a gem-dimethyl group in 
DM4-ADC that slows the reduction of the disulfide bond by gluthathione.23,24 
 
1.3.1.3 Tumor-Specific Protease Linkers 
Generally, ADCs that contain an acid-labile linker or a disulfide bond have poor 
plasma stability because the linker can be rapidly hydrolyzed or reduced, respectively, in 
the plasma to release the drug prior to reaching the target site. To overcome this problem, 
a peptide bond linker was developed because proteases normally are not very active 
outside of the cell cytoplasm.25 Monomethyl auristatin E (MMAE) was linked to valine-
citrulline dipeptide that was connected to a maleimide group; the maleimide linker was 
attached to cysteine residues on the antibody to give MMAE-ADC (Fig. 5). The 
dipeptide is recognized by cathepsin B for hydrolysis to release MMAE in its active 
form.26 It has been shown that the use of a dipeptide linker (i.e., valine-citrulline) 
increases the half-life of the ADC in the human plasma by nearly 100-fold compared to 
the MMAE linked to antibody by a hydrazone linker.27 Because the rate of enzymatic 
 11 
 
 
 
 
H
N
S
S
DM4
O
n
 
 
 
Dimethyl 
 
Disulfide 
 
Figure 4. Conjugation of DM1 or DM4 drug was achieved using lysine residues near 
the surface of the mAb. The presence of gem-dimethyl groups adjacent to the disulfide 
group in DM4 drug increased the half-life by more than twofold compared to DM1, 
which does not have gem-dimethyl groups. 
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Figure 5. Monomethyl auristatin E (MMAE) was conjugated to a dipeptide consisting 
of valine and citrulline as the enzyme-cleavable linker. The MMAE-dipeptide is 
conjugated to cysteine residue(s) of the mAb via a malemide linker. 
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cleavage depends on the dipeptide sequence, the half-life the MMAE ADC can be partly 
regulated by sequence of the dipeptide linker.  
 
1.3.2 Noncleavable Linkers 
1.3.2.1 Thioether 
DM1 was conjugated to a mAb via a thioether bond (Fig. 6). Because this linker 
cannot be cleaved by enzyme or acid, it is proposed that the drug is released in the 
lysosome after the mAb is degraded.  It is thought that the active substance is the DM1 
drug linked to the lysine residue of the mAb via a malemide group. The thioether-linked 
DM1 conjugate has a half-life of 134 hours.28 One caution in using this type of linker is 
that, if the mAb has poor cellular uptake, the non-cleavable linker should not be used 
because the drug cannot be released from the conjugate. 
 
1.3.2.2 Peptibody 
Peptibody is a conjugate between peptides and antibodies or antibody fragments 
(Fig. 7). Unlike conventional ADCs with chemical conjugation, a peptibody is produced 
upon expression of the antibody with a peptide sequence attached to it.29 This process 
eliminates the need to separately synthesize the peptide and express the protein. Currently, 
peptibody formation is being utilized to improve the half-life of the peptide in systemic 
circulation.29 Romiplostim (Nplate®) is the only FDA-approved peptibody on the 
market.30 It was approved in 2008 for the treatment of chronic immune thrombocytopenic 
purpura (ITP).30 Romiplostim is the result of a fusion between an Fc-fragment of mAb 
(IgG1) and a 14-amino acid peptide agonist of a thrombopoietin (TPO), receptor called 
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Figure 6. To increase the drug half-life, DM1 is conjugated to a thioether linker to the 
mAb via a malemide group that is attached to lysine residues.  
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IgG1 Fc domain TPO peptide agonist 
Figure 7. The Fc domain of the IgG1 antibody (dark gray) prolongs the half-life of 
Romiplostim in vivo, whereas the TPO agonist (black) provides biological activity.  
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AF12505, which stimulates platelet production.30 Here, two molecules of AF12505 are 
fused to an Fc-fragment of mAb to enhance peptibody activity because the two peptide 
fragments presumably bind simultaneously to the dimeric form of the receptor. This idea 
was modeled after the finding that the dimeric form of the peptide agonist was more 
active than the monomeric form.29 This is the first design of a peptibody for increasing 
receptor-binding affinity as well as extending the circulation half-life of the peptide.  
 
1.4 PEPTIDE-DRUG CONJUGATES 
Peptides are generally defined as having a chain of no more than 50 amino acids. 
Unlike proteins, peptides may exhibit a high degree of secondary structure, but may or 
may not have tertiary structure.31 The advantage of a peptide over an antibody is the 
relative ease of synthesis and structure manipulation compared to an antibody. Once a 
target has been identified, peptide synthesis and purification can be achieved in a matter 
of just a few weeks. In contrast, it takes years to develop an efficient method to produce 
and purify large quantity of antibodies. However, peptides tend to have lower 
specificities than antibodies in recognizing target cell surface receptors. A major 
disadvantage of a peptide compared to an antibody is its rapid rate of renal clearance 
because kidneys do not filter out proteins larger than 50 kDa.32 Furthermore, peptides 
normally have low half-lives ranging anywhere from a few hours to minutes.32 To combat 
against renal clearance and exposure to exopeptidases, scientists have attached 
polyethylene glycol (PEG) to the N- and C-termini of peptides to add bulk and protect 
from enzymes.33 A variety of peptides have been investigated for delivering drugs to 
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specific cells, including cell-penetrating peptides, bombesin peptide, LHRH peptide, 
RGD peptide, and ICAM-1 peptide.34-38 
 
1.4.1 Cell-Penetrating Peptides 
Highly cationic cell-penetrating peptides (CPP) can cross the cell lipid bilayer 
without the need for a specific receptor.39 Although the mechanism of cellular uptake of 
CPP has not been fully elucidated, this is an ideal molecule to deliver drugs to a site of 
action where no suitable receptors exist. CPP contain either a predominant population of 
arginine residues or largely lysine residues.32 Penetratin, TAT, and VP22 have been used 
to delivery biologically active proteins.39 TAT is a trans-activator of transcription derived 
from HIV, and the arginine-rich (11 amino acid) peptide sequence (TAT47-57; 
YGRKKRRQRRR) is involved in cellular transduction.38 As mentioned above, the 
mechanism of CPP crossing cell membranes is not exactly clear, but evidence for both 
endosomal and non-endosomal mechanisms has been reported.40,41 The endosomal 
pathway of CPP occurs due to a decrease in pH in the endosome, trapping the positively 
charged amino acid residues.42 If the goal of delivery is to avoid transport to the nucleus, 
both the CPP and the drug cargo must not be highly positively charged and, therefore, 
formulated to avoid this possibility. An application of a CPP-drug conjugate is illustrated 
using a δPKC inhibitor, KAI-9803, which is used in stroke patients. Here, the compound 
is conjugated to TAT47-57 via a disulfide bond where the conjugate showed a reduction in 
apoptotic cell death after ischemia.42 Although cell-penetrating peptides have provided 
success in delivering drugs into cells, they lack specificity to recognize receptors as 
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targets to deliver drugs to the optimal site of action. Up to now, no successful clinical 
applications of CPP-drug conjugates are available for treating patients. 
 
1.4.2 Drug Targeting With Cell Adhesion Peptides 
The upregulation of adhesion molecules on the surface of leukocytes and 
endothelial cells has been correlated with inflammation and some forms of cancers (i.e., 
lung and pancreatic cancers).3,5 LFA-1 receptor is exclusively expressed on leukocytes, 
and has been shown to uptake and internalize cIBR peptide derived from the ICAM-1 
protein.35,43,44 Methotrexate (MTX) has been linked to cIBR peptide to give MTX-cIBR 
conjugate for delivering MTX to activated leukocytes to suppress inflammation in 
rheumatoid arthritis (RA). MTX is being used to treat RA; however, chronic use of MTX 
produces adverse side effects. Therefore, targeting MTX using peptides may alleviate 
unwanted side effects and improve efficacy.  MTX-cIBR was effective in suppressing 
rheumatoid arthritis in the collagen-induced arthritis (CIA) mouse model and rat adjuvant 
arthritis model.45 MTX-cIBR has lower in vivo toxicity than MTX alone in CIA mouse 
model, suggesting that cIBR peptide selectively targets MTX to leukocytes in vivo. In 
vitro, MTX-cIBR was more toxic to LFA-1-expressing cells than to cells without LFA-1 
on the cell surface, indicating that LFA-1 receptor contributes to the activity of MTX-
cIBR. 
 
1.4.3 Multifunctional Peptides and Proteins 
Recently, the concept of simultaneously modulating two different receptors to 
control biological mechanism was explored in autoimmune diseases. Siahaan et al. 
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explored the possibility of altering the differentiation and proliferation of T cells by 
controlling the formation of immunological synapse.46 Bifunctional peptide inhibitors and 
insert-domain (I-domain) antigen conjugates (IDAC) are respective peptide-peptide and 
peptide-protein conjugates that can bind two different receptors (MHC-II and ICAM-1) 
on the surface of antigen-presenting cells (APC) and can alter the differentiation of naïve 
T cells to favor regulatory T cells and generate immune tolerance in autoimmune diseases.  
 
1.4.3.1 Bifunctional Peptide Inhibitors 
A bifunctional peptide inhibitor (BPI; Fig. 8A) molecule is a conjugate between 
an antigenic peptide and a cell adhesion peptide that can simultaneously bind to their 
respective receptors (MHC-II and ICAM-1) on APC to elicit biological activity. One 
example of BPI molecules is PLP-BPI, which is a conjugate of PLP peptide and LABL 
peptide that is linked via a chain of aminocaproic acids.  In PLP-BPI, PLP and LABL 
peptides were proposed to simultaneously bind to MHC-II and ICAM-1, respectively, on 
the surface of APC.47 Therefore, linking PLP and LABL peptide is hypothesized to 
prevent the formation of the immunological synapse during the interaction of APC and T 
cells for T-cell activation.47 The immunological synapse is a bull’s eye structure at the 
interface of APC and T cells made of a cluster of Ag-MHC-II/TCR (Signal-1) at the 
center and a cluster of ICAM-1/LFA-1 (Signal-2) at the periphery.47 Several different 
bifunctional peptide inhibitor (BPI) molecules such as PLP-BPI, GAD-BPI, and CII-BPI 
have been shown to suppress experimental autoimmune encephalomyelitis (EAE), Type-
1 diabetes, and rheumatoid arthritis, respectively.2,6,46,48 The common mechanism of BPI 
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Figure 8. (A) Representative construct of bifunctional peptide inhibitors. 
Aminocaproic acid with an alternating glycine residue is commonly used as the 
spacer. The N-terminus is capped with an acetyl group, and the C-terminus is capped 
with an amide group. (B) IDAC is a conjugate between an antigenic peptide and the I-
domain. The linker between the two compounds is N-[γ-maleimidobutyryloxy]-
succinimide ester. 
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molecules is that they induce tolerance by stimulating the differentiation/proliferation of 
T-regs and suppressing the inflammatory Th17 cells.2,48 
 
1.4.3.2 I-domain-Antigenic Peptide Conjugate (IDAC) 
Proteins (i.e., cytokines and mAbs) have been successfully used as therapeutics to 
treat various diseases. Proteins are known to bind specific receptors and have been 
investigated as conjugates for delivering drugs to specific types of cells. As mentioned 
above, peptibodies, which are conjugates between a peptide and a fragment of antibody, 
have been used to improve systemic circulation of peptide drugs. However, the peptide-
protein conjugation has not been evaluated for simultaneous binding to two different cell 
surface receptors for controlling pathological conditions. The Siahaan group designed 
IDAC molecules as conjugates between antigenic peptides and the I-domain protein. The 
I-domain is a fragment of the alpha subunit of LFA-1 that binds to domain-1 of ICAM-
1.47 Using fluorescein-5’-isthiocyanate (FITC)-I-domain conjugate, it was found that the 
I-domain can bind to ICAM-1 and become internalized by the effector cell.49 Recently, 
the I-domain has been conjugated to an antigenic peptide (PLP139-151) to give IDAC 
molecules. This was accomplished by utilizing N-[γ-maleimidobutyryloxy]succinimide 
ester (GMBS), where the free lysines of the I-domain were conjugated to the succinimide 
group of GMBS, and the maleimide group was subsequently reacted with the sulfur 
group of the cysteine residue located on the C-terminus of PLP139-151-Cys (Fig. 8B). As in 
PLP-BPI, it is proposed that the IDAC molecules simultaneously bind to target receptors 
MHC-II and ICAM-1 on the surface of antigen-presenting cells.49 The IDAC molecules 
effectively suppressed experimental autoimmune encephalomyelitis (EAE) in the mouse 
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model, an animal model for multiple sclerosis. It was found that IDAC molecules 
suppress EAE by enhancing the production of regulatory T cells (T-reg) and suppressing 
Th17 cells. 
 
1.5 CONCLUSIONS 
Using peptides and proteins as cargoes to carry drugs has generated an increasing 
amount of interest, especially in the field of cancer research. Although success has varied, 
the results have been promising. One strategy is to consider developing conjugates that 
have dual activities to potentially modulate two or more receptors. For many immune 
disorders, effector cells require two or more signals to become activated. Proof-of-
concept studies suggested that BPI and IDAC could be used to suppress autoimmune 
diseases. Liposomal and polymer technologies containing conjugates of multiple peptide 
sequences specific for different receptors have also had success.31,50 The hope is that 
conjugates will provide a new avenue for the development of better drugs. Therefore, the 
overall objective of this work was to investigate the ability of peptide/protein conjugates 
to deliver antigenic peptides to antigen-presenting cells to suppress autoimmune disease 
in mouse models. To investigate this, the following specific aims were undertaken: 
Specific Aim 1 (Chapter 2): To investigate the ability of an LFA-1 I-domain antigen 
conjugate (IDAC) to target APC and suppress EAE in both vaccine-like and prophylactic 
fashions. 
Specific Aim 2 (Chapter 3): To design a colloidal gel formulation of a BPI molecule for 
controlled-release delivery in a vaccine-like manner to suppress EAE. 
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Specific Aim 3 (Chapter 4): To investigate the utility of BPI to target APC to suppress 
other autoimmune diseases such as rheumatoid arthritis in the mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
1.6 REFERENCES 
1 Kaufmann, A. M. & Krise, J. P. Lysosomal sequestration of amine-containing 
drugs: analysis and therapeutic implications. J Pharm Sci 96, 729-746 (2007). 
2 Kobayashi, N. et al. Prophylactic and therapeutic suppression of experimental 
autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin 
Immunol 129, 69-79 (2008). 
3 Lee, S. J. & Benveniste, E. N. Adhesion molecule expression and regulation on 
cells of the central nervous system. J Neuroimmunol 98, 77-88 (1999). 
4 Olsen, E. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for 
the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19, 376-388 (2001). 
5 Seidel, M. F., Keck, R. & Vetter, H. ICAM-1/LFA-1 expression in acute 
osteodestructive joint lesions in collagen-induced arthritis in rats. J Histochem 
Cytochem 45, 1247-1253 (1997). 
6 Kobayashi, N., Kobayashi, H., Gu, L., Malefyt, T. & Siahaan, T. J. Antigen-
specific suppression of experimental autoimmune encephalomyelitis by a novel 
bifunctional peptide inhibitor. J Pharmacol Exp Ther 322, 879-886 (2007). 
7 Trail, P. A. et al. Cure of xenografted human carcinomas by BR96-doxorubicin 
immunoconjugates. Science 261, 212-215 (1993). 
8 Walsh, G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28, 917-924 
(2010). 
9 Hamann, P. R. et al. An anti-CD33 antibody-calicheamicin conjugate for 
treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13, 40-46 
(2002). 
 25 
10 Hamann, P. R. et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 
antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. 
Bioconjug Chem 13, 47-58 (2002). 
11 Linenberger, M. L. CD33-directed therapy with gemtuzumab ozogamicin in acute 
myeloid leukemia: progress in understanding cytotoxicity and potential 
mechanisms of drug resistance. Leukemia 19, 176-182 (2005). 
12 Linenberger, M. L. et al. Multidrug-resistance phenotype and clinical responses to 
gemtuzumab ozogamicin. Blood 98, 988-994 (2001). 
13 Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive 
lymphomas. N Engl J Med 363, 1812-1821 (2010). 
14 Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the 
treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 12, 350-360 
(2010). 
15 Hursey, M. et al. Specifically targeting the CD22 receptor of human B-cell 
lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk 
Lymphoma 43, 953-959 (2002). 
16 Kreitman, R. J. Recombinant immunotoxins for the treatment of chemoresistant 
hematologic malignancies. Curr Pharm Des 15, 2652-2664 (2009). 
17 Pastan, I., Hassan, R., FitzGerald, D. J. & Kreitman, R. J. Immunotoxin treatment 
of cancer. Annu Rev Med 58, 221-237 (2007). 
18 Goldsmith, S. J. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin 
Nucl Med 40, 122-135 (2010). 
 26 
19 Linden, O. et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's 
lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 
monoclonal antibody, epratuzumab. Clin Cancer Res 11, 5215-5222 (2005). 
20 Tolcher, A. W. et al. Randomized phase II study of BR96-doxorubicin conjugate 
in patients with metastatic breast cancer. J Clin Oncol 17, 478-484 (1999). 
21 Stella, V. J. Prodrugs : challenges and rewards.  (Springer, 2007). 
22 Ducry, L. & Stump, B. Antibody-drug conjugates: linking cytotoxic payloads to 
monoclonal antibodies. Bioconjug Chem 21, 5-13 (2010). 
23 Erickson, H. K. et al. Antibody-maytansinoid conjugates are activated in targeted 
cancer cells by lysosomal degradation and linker-dependent intracellular 
processing. Cancer Res 66, 4426-4433 (2006). 
24 Xie, H., Audette, C., Hoffee, M., Lambert, J. M. & Blattler, W. A. 
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, 
cantuzumab mertansine (huC242-DM1), and its two components in mice. J 
Pharmacol Exp Ther 308, 1073-1082 (2004). 
25 Koblinski, J. E., Ahram, M. & Sloane, B. F. Unraveling the role of proteases in 
cancer. Clin Chim Acta 291, 113-135 (2000). 
26 Toki, B. E., Cerveny, C. G., Wahl, A. F. & Senter, P. D. Protease-mediated 
fragmentation of p-amidobenzyl ethers: a new strategy for the activation of 
anticancer prodrugs. J Org Chem 67, 1866-1872 (2002). 
27 Doronina, S. O. et al. Development of potent monoclonal antibody auristatin 
conjugates for cancer therapy. Nat Biotechnol 21, 778-784 (2003). 
 27 
28 Polson, A. G. et al. Antibody-drug conjugates for the treatment of non-Hodgkin's 
lymphoma: target and linker-drug selection. Cancer Res 69, 2358-2364 (2009). 
29 Cwirla, S. E. et al. Peptide agonist of the thrombopoietin receptor as potent as the 
natural cytokine. Science 276, 1696-1699 (1997). 
30 Molineux, G. & Newland, A. Development of romiplostim for the treatment of 
patients with chronic immune thrombocytopenia: from bench to bedside. Br J 
Haematol 150, 9-20 (2010). 
31 Majumdar, S. & Siahaan, T. J. Peptide-mediated targeted drug delivery. Med Res 
Rev (2010). 
32 Sato, A. K., Viswanathan, M., Kent, R. B. & Wood, C. R. Therapeutic peptides: 
technological advances driving peptides into development. Curr Opin Biotechnol 
17, 638-642 (2006). 
33 Werle, M. & Bernkop-Schnurch, A. Strategies to improve plasma half life time of 
peptide and protein drugs. Amino Acids 30, 351-367 (2006). 
34 Chen, X., Plasencia, C., Hou, Y. & Neamati, N. Synthesis and biological 
evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-
targeted drug delivery. J Med Chem 48, 1098-1106 (2005). 
35 Gursoy, R. N. & Siahaan, T. J. Binding and internalization of an ICAM-1 peptide 
by the surface receptors of T cells. J Pept Res 53, 414-421 (1999). 
36 Nagy, A. et al. Design, synthesis, and in vitro evaluation of cytotoxic analogs of 
bombesin-like peptides containing doxorubicin or its intensely potent derivative, 
2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A 94, 652-656 (1997). 
 28 
37 Nagy, A. et al. Cytotoxic analogs of luteinizing hormone-releasing hormone 
containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times 
more potent. Proc Natl Acad Sci U S A 93, 7269-7273 (1996). 
38 Vives, E., Brodin, P. & Lebleu, B. A truncated HIV-1 Tat protein basic domain 
rapidly translocates through the plasma membrane and accumulates in the cell 
nucleus. J Biol Chem 272, 16010-16017 (1997). 
39 Lindgren, M., Hallbrink, M., Prochiantz, A. & Langel, U. Cell-penetrating 
peptides. Trends Pharmacol Sci 21, 99-103 (2000). 
40 Magzoub, M. & Graslund, A. Cell-penetrating peptides: [corrected] from 
inception to application. Q Rev Biophys 37, 147-195 (2004). 
41 Wagstaff, K. M. & Jans, D. A. Protein transduction: cell penetrating peptides and 
their therapeutic applications. Curr Med Chem 13, 1371-1387 (2006). 
42 Langel, U. l. Cell-penetrating peptides : methods and protocols.  (Humana Press, 
2011). 
43 Jois, D. S. et al. Inhibition of homotypic adhesion of T-cells: secondary structure 
of an ICAM-1-derived cyclic peptide. J Pept Res 49, 517-526 (1997). 
44 Majumdar, S., Kobayashi, N., Krise, J. P. & Siahaan, T. J. Mechanism of 
internalization of an ICAM-1-derived peptide by human leukemic cell line HL-
60: influence of physicochemical properties on targeted drug delivery. Mol Pharm 
4, 749-758 (2007). 
45 Majumdar, S. Targeted drug delivery to leukocytes with ICAM-1 derived peptides 
Ph.D. thesis, University of Kansas, (2008). 
 29 
46 Murray, J. S. et al. Suppression of type 1 diabetes in NOD mice by bifunctional 
peptide inhibitor: modulation of the immunological synapse formation. Chem Biol 
Drug Des 70, 227-236 (2007). 
47 Manikwar, P., Kiptoo, P., Badawi, A. H., Buyuktimkin, B. & Siahaan, T. J. 
Antigen-specific blocking of CD4-specific immunological synapse formation 
using BPI and current therapies for autoimmune diseases. Med Res Rev (2011). 
48 Ridwan, R. et al. Antigen-specific suppression of experimental autoimmune 
encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization 
and pharmacokinetics. J Pharmacol Exp Ther 332, 1136-1145 (2010). 
49 Manikwar, P. et al. Utilization of I-domain of LFA-1 to Target Drug and Marker 
Molecules to Leukocytes. Theranostics 1, 277-289 (2011). 
50 Chittasupho, C., Shannon, L., Siahaan, T. J., Vines, C. M. & Berkland, C. 
Nanoparticles targeting dendritic cell surface molecules effectively block T cell 
conjugation and shift response. ACS Nano 5, 1693-1702 (2011). 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
Utilizing the I-domain of LFA-1 to target antigenic peptides for suppressing the 
immune response in the EAE animal model 
 
 
 
 
 
 
 
 
 
 
 31 
2.1 INTRODUCTION 
Multiple sclerosis (MS) is an autoimmune disease caused by demyelination of the 
myelin sheath, which protects the neurons in the central nervous system (CNS). Without 
the protection of the myelin sheath proteins, nerve impulses are either disrupted or 
slowed down. While the triggers of MS have not been clearly elucidated, several factors 
such as Epstein-Barr virus (EBV) infection, genetic predisposition, and environmental 
effects are thought to play key roles in its development.1-4 Just as in rheumatoid arthritis 
and type-1 diabetes, MS is a result of activation of a subpopulation of autoreactive T cells 
that demyelinate the nerve fibers in CNS.1,4,5 While there is no cure for MS, many of 
today’s therapies, including biologic drugs such as such as interferons (Avonex®, 
Betaseron®), antibodies (Tysabri®), and antineoplastics (mitoxantrone), focus on slowing 
down or altering the disease progression.6 A criticism of these current therapies is that 
they do not target the cause of MS but rather suppress the general immune system, 
leading to potential serious side effects. Therefore, there is a need to investigate a new 
and more specific way to control the immune response generated in an autoimmune 
disease such as MS without suppressing the general immune response. 
To investigate new therapeutics, the Siahaan lab group developed a novel way to 
target antigenic peptides to antigen presenting cells (APC) to control the activation of a 
subpopulation of T cells specific to a particular autoimmune disease. In this approach, a 
cell adhesion peptide was conjugated to an antigenic peptide to make bifunctional peptide 
inhibitors (BPI) with the hypothesis that the BPI molecules target the APC and shift the 
activation of T cells from an inflammatory to a regulatory phenotype.7-9 Previously, BPI 
molecules have been shown to successfully suppress the progression of autoimmune 
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diseases such as MS, Type 1 diabetes, and rheumatoid arthritis in animal models.7-10 It 
was proposed that BPI molecules bind simultaneously to the major histocompatibility 
complex class II (MHC-II) and ICAM-1 on APC to block immunological synapse 
formation at the T cell-APC interface, subsequently altering T cell differentiation from 
inflammatory to regulatory.7-10 PLP-BPI is a conjugate between an antigenic peptide 
(PLP139-151) and a cell adhesion peptide (LABL) derived from the I-domain of 
lymphocyte function-associated antigen-1 (LFA-1) and tethered together by a linker 
molecule. Unfortunately, BPI molecules can deliver only one antigenic peptide at a time 
and cannot deliver multiple antigens when antigenic spreading has occurred. Therefore, 
there is also a need to find a way to simultaneously deliver multiple antigens to APC to 
overcome the problem of antigenic spreading in a particular autoimmune disease. 
In this study, I-domain-antigen conjugate (IDAC) molecules derived from the 
I-domain protein were conjugated with multiple proteolipid protein (PLP) peptides. The 
experimental autoimmune encephalomyelitis (EAE) mouse model was treated with IDAC 
using prophylactic and vaccine-like delivery methods. The I-domain of LFA-1 interacts 
with the first domain (D1) of ICAM-1 thus providing a scheme to target PLP antigen to 
APC.11 Because the I-domain has multiple lysine residues, several PLP peptides can be 
conjugated to one molecule of the I-domain. In this study, IDAC-1 and IDAC-3 
molecules were synthesized by conjugating PLP-Cys-OH and Ac-PLP-Cys-NH2 peptides, 
respectively, to several lysine groups of the I-domain. The purified IDAC molecules were 
characterized using mass spectrometry and circular dichroism (CD) spectroscopy, and 
their efficacies were evaluated in the EAE mouse model. In both prophylactic and 
vaccine-like delivery methods, IDAC molecules effectively suppressed EAE compared to 
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PBS. The cytokine production data suggested that IDAC molecules stimulate the 
proliferation of regulatory and suppressor cells. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Animals 
SJL/J female mice were purchased from Charles River Laboratories, Inc. 
(Wilmington, MA) and subsequently housed under specific pathogen-free conditions at 
the animal facility at The University of Kansas approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). All experimental 
procedures using live mice were approved by the Institutional Animal Care and Use 
Committee (IACUC) at The University of Kansas. 
 
2.2.2 Peptide Synthesis 
All peptides used in this study (Table 1) were synthesized using a 
9-fluorenylmethyloxycarbonyl-protected solid-phase peptide chemistry on an automated 
peptide synthesizer (Pioneer; Perceptive Biosystems, Framingham, MA).  The peptides 
along with the protecting group were removed from the resin using trifluoroacetic acid 
(TFA) in the presence of appropriate scavengers. The crude peptides were purified using 
semi-preparative reversed-phase high-performance liquid chromatography (RP-HPLC) 
with a C18 column. A gradient method was used for purification with solvent A (94.9% 
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water, 5% acetonitrile, and 0.1% trifluoroacetic acid) and solvent B (100% acetonitrile). 
HPLC with an analytical C18 column was used to determine the peptide purity (>96%). 
The identity of the peptides was confirmed using matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. 
 
2.2.3 I-domain Preparation 
The I-domain protein was over-expressed, refolded, and purified as previously 
described.12 The identity, purity, and secondary structure of the protein were confirmed 
by mass spectrometry, SDS-PAGE, and CD, respectively.  
 
2.2.4 Synthesis of IDAC-1 and -3 
N-[γ-maleimidobutyryloxy]succinimide ester (GMBS) was first reacted at a 
tenfold molar excess with the free lysine residues of the I-domain (2 mg/ml) for 1 h in 
PBS to generate GMB-I-domain. Subsequent purification of the reaction mixture was 
done using size-exclusion chromatography (SEC). Then, the thiol group on the Cys 
residue of PLP-Cys-OH and Ac-PLP-Cys-NH2 peptides was reacted at a 15-molar excess 
with the newly formed maleimide groups on the GMB-I-domain (2 mg/ml) at pH 8.5 to 
give IDAC-1 and -3, respectively. After a 1-hour reaction, the pH of the solution was 
adjusted to 7.4, and the resulting mixture was purified using SEC. The purity, identity, 
and conformation of IDAC-1 and -3 were determined using SDS-PAGE, mass 
spectrometry (LC ESI-MS), and CD, respectively.  
 
2.2.5 Induction of EAE and Efficacy Studies 
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Six-to-eight week old SJL/J female mice were immunized subcutaneously with 
200 µg PLP139-151 peptide in a 0.2 ml emulsion consisting of equal volumes of PBS and 
complete Freund’s adjuvant (CFA) containing killed mycobacterium tuberculosis strain 
H37RA at a final concentration of 4 mg/ml (Difco, Detroit, MI).  The PLP/CFA emulsion 
was administered to regions above the shoulder and the flanks (total of 4 sites, 50 µl at 
each injection site). In addition, 200 ng of pertussis toxin was injected intraperitoneally 
on the day of immunization (day 0) and 2 days post-immunization.  
The mice then received either intravenous or subcutaneous injections of IDAC 
(10 or 26 nmol/injection) or peptides (100 nmol/injection for Ac-PLP-BPI-NH2-2 or 50 
nmol/injection/mouse for Ac-PLP-cIBR1-NH2). The prophylactic disease suppression 
was carried out with subcutaneous or intravenous injections of IDAC molecules on days 
4 and 7, or BPI molecules on days 4, 7, and 10. Mice receiving vaccine-like treatment 
were given subcutaneous injections of IDAC and BPI molecules at 11, 8, and 5 days prior 
to the induction of disease. As negative controls, mice were treated with PBS, I-domain, 
and GMB-I-domain. Disease progression was evaluated by monitoring the change in 
weight of the mice and clinical scoring based on the severity of nerve damage ranging 
from 0 to 5: 0–no clinical symptoms of disease; 1–tail weakness or limp tail; 2–
paraparesis (weakness or partial paralysis of one or two hind limbs); 3–paraplegia 
(complete paralysis of two hind limbs); 4–paraplegia with forelimb weakness or 
paralysis; 5–moribund (at this point, the affected mice were euthanized). 
 
2.2.6 Determination of Cytokine Levels In Vitro 
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Representative spleens for each group (IDAC-3 or PBS) from Study 2 were 
harvested from female SJL/J (H-2S) mice on days 13 and 35. Splenocytes were dispersed 
by gently smashing the spleen using the coarse portion of a 1 ml syringe in a petri dish 
containing RPMI 1640 medium (10% FBS, 0.05 M BME). The cells were then filtered 
through a 40 micrometer strainer. After centrifugation, the red blood cells were lysed 
using “ACK lysis buffer,” and the remaining white blood cells were washed three times 
with medium. Splenocytes (5 × 106 cells/ml) were cultured in parallel in the presence of 
20 µM PLP and blank RPMI medium. Supernatants were collected at a 72 h time-point 
for the measurement of cytokine levels. The samples were then analyzed using a fully 
quantitative ELISA-based Q-PlexTM Mouse Cytokine-Screen (Quansys Biosciences, 
Logan, UT). 
 
2.2.7 Statistical Analysis 
 Statistical differences among the groups in clinical disease scores were 
determined by calculating the average score for each mouse from day 12 to day 17 by 
one-way analysis of variance followed by Fisher’s least significant difference.  Statistical 
differences in body weight among groups were also analyzed in the same fashion, but 
from day 12 to day 24. Comparison of cytokine concentrations was also performed by 
one-way analysis of variance. All analyses were performed using StatView (SAS Institute, 
Cary, NC). 
 
2.3 RESULTS 
2.3.1 Synthesis and Characterization of IDAC-1 and -3 
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 IDAC-1 and -3 were prepared by randomly conjugating the free amine groups of 
the I-domain with the N-hydroxysuccinimide group of GMBS, yielding GMB-I-domain. 
The resulting GMB-I-domain was then reacted with the thiol group of the Cys residue on 
PLP-Cys-OH or Ac-PLP-Cys-NH2, yielding IDAC-1 and -3, respectively. Then, the 
resulting mixture was purified using size-exclusion column chromatography, and the 
eluted fractions were subsequently analyzed using SDS-PAGE (Fig. 2.1A).  Multiple 
bands were seen on SDS-PAGE due to the varying number of conjugated peptides on the 
I-domain. The earlier lanes on the gel have bands at a higher molecular weight compared 
to the later lanes, which corresponded to the order of elution of IDAC from the SEC. 
Analysis with circular dichroism showed that both IDAC-1 and -3 have spectra similar to 
that of the I-domain, indicating that multiple conjugations did not alter the secondary 
structure (Fig. 2.1B). The deconvoluted LC-MS data showed that both IDAC molecules 
had 0–5 PLP-Cys peptides conjugated per I-domain, with an average of 2.5 PLP-Cys 
peptides per I-domain molecule (Fig. 2.1C). 
 
2.3.2 Suppression of EAE by IDAC-1 and -3 
 To test whether the I-domain and GMB-I-domain had in vivo efficacy, three 
groups of mice were treated with two intravenous injections of the I-domain or 
GMB-I-domain (26 nmol/injection) as well as PBS on days 4 and 7. Although there was a 
slight delay in the onset of the disease, neither the I-domain nor GMB-I-domain 
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20 kDa 
IDAC-3 fractions after SEC purification 
1       2      3       4      5      6     7 
Figure 2.1 Characterization of IDAC-1 and -3 were done by SDS-PAGE gel (A), CD 
(B), and mass spectrometry (C). Figure 2.1A: SDS-PAGE analysis of the conjugate 
following separation using SEC and after staining with Coomassie blue: molecular 
weight marker (lane 1), fractions of conjugated IDAC-3 in the order of elution from 
SEC (lanes 3–7). 
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Figure 2.1B: CD spectra of the parent I-domain (square), IDAC-1 (open circle) and 
IDAC-3 (closed circle). 
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Figure 2.1C: Deconvoluted mass spectra of LC ESI-MS analysis of IDAC-1 and 
IDAC-3. 
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significantly suppressed the progress of EAE compared to the PBS-treated mice, as 
determined by the clinical score (Fig. 2.2A), change in body weight (Fig. 2.2B), and the 
incidence of disease (Fig. 2.2C). 
 In the second study, the efficacies of IDAC-1 and IDAC-3 with uncapped and 
capped PLP peptides, respectively, were compared upon intravenous injections of 26 
nmol/injection on days 4 and 7; the control group was injected with PBS. Clinical scores 
(Fig. 2.3A) indicated that both proteins delayed the onset of disease and were 
significantly better at suppressing EAE than to PBS (p < 0.0005, through days 12–17). 
Furthermore, IDAC-3 was better than IDAC-1 in suppressing EAE (p < 0.005, through 
days 12–17), suggesting that capping the antigenic PLP peptide at both ends yields a 
more efficacious product. The body weight change for IDAC-1- and IDAC-3-treated 
animals supported the clinical score data; two injections of IDAC-1 and -3 were 
significantly more effective than PBS in suppressing disease (Fig. 2.3B, p < 0.05 through 
days 12–24). In addition, there were delays in disease incidence in IDAC-1- and IDAC-3-
treated animals (Fig. 2.3C). 
 After establishing that IDAC-3 was a better candidate to suppress EAE, the third 
study was aimed at evaluating an alternative route of injection (i.e., subcutaneous or s.c.), 
dose response to determine therapeutic index, and optimal timing of IDAC-3 injections 
(Fig. 2.4). First, IDAC-3 injected s.c. (26 nmol/injection) on days 4 and 7 was 
significantly more efficacious than PBS in suppressing EAE as shown by clinical scores 
(p < 0.005, through days 12–17; Fig. 2.4A), change in body weight of the mice (p < 
0.005, through days 12–24; Fig. 2.4B), and disease incidence (Fig. 2.4C). It was difficult 
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Figure 2.2A In vivo activity of I-domain, GMB-I-domain, and PBS in mouse EAE 
model evaluated by clinical scores. After immunization with PLP peptide in CFA, the 
mice received i.v. injections of 26 nmol/injection/day of I-domain or GMB-I-domain 
on days 4 and 7. Control mice were treated with PBS on days 4, 7, and 10. Disease 
progression was evaluated using (A) clinical disease scores, (B) change in body 
weight, and (C) incidence of disease. Although there was a slight delay in the onset of 
disease, neither protein significantly suppressed the progress of EAE compared to the 
PBS-treated mice. The results are expressed as the mean ± S.E. (n ≥ 6). 
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Figure 2.2B In vivo activity of I-domain, GMB-I-domain, and PBS in mouse EAE 
model evaluated using change in body weight. After immunization with PLP peptide 
in CFA, the mice received i.v. injections of 26 nmol/injection/day of I-domain or 
GMB-I-domain on days 4 and 7. Control mice were treated with PBS on days 4, 7, and 
10. There are no significant differences between I-domain and GMB-I-domain 
compared to the PBS-treated mice. The results are expressed as the mean ± S.E. (n ≥ 
6). 
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Figure 2.2C In vivo activity of I-domain, GMB-I-domain, and PBS in mouse EAE 
model evaluated using incidence of disease. After immunization with PLP peptide in 
CFA, the mice received i.v. injections of 26 nmol/injection/day of I-domain or 
GMB-I-domain on days 4 and 7. Control mice were treated with PBS on days 4, 7, and 
10. I-domain and GMB-I-domain delayed the onset of disease compared to the PBS-
treated mice, but did not fully suppress disease.  
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Figure 2.3A Comparison of the in vivo activity of IDAC-1, IDAC-3, 
Ac-PLP-cIBR1-NH2, and PBS in the mouse EAE model using clinical disease scores. 
After immunization with PLP peptide in CFA, the mice received i.v. injections of 26 
nmol/injection/day of IDAC-1 or IDAC-3 on days 4 and 7. For the 
Ac-PLP-cIBR1-NH2 treatment group, the mice received i.v. injections of 50 
nmol/injection/day of the peptide on days 4, 7, and 10. Control mice were treated with 
PBS on days 4, 7, and 10. IDAC-1 and IDAC-3 delayed the onset of disease and were 
significantly better at suppressing EAE than to PBS (p < 0.0005, through days 12–17). 
IDAC-3 was better than IDAC-1 in suppressing EAE (p < 0.005, through days 12–17). 
The results are expressed as the mean ± S.E. (n ≥ 6). 
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Figure 2.3B Comparison of the in vivo activity of IDAC-1, IDAC-3, 
Ac-PLP-cIBR1-NH2, and PBS in the mouse EAE model using change in body weight. 
After immunization with PLP peptide in CFA, the mice received i.v. injections of 26 
nmol/injection/day of IDAC-1 or IDAC-3 on days 4 and 7. For the 
Ac-PLP-cIBR1-NH2 treatment group, the mice received i.v. injections of 50 
nmol/injection/day of the peptide on days 4, 7, and 10. For the control mice, they were 
treated with PBS on days 4, 7, and 10. Two injections of IDAC-1 and IDAC-3 were 
significantly more effective than PBS in suppressing disease (p < 0.05 through days 
12–24). The results are expressed as the mean ± S.E. (n ≥ 6). 
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Figure 2.3C Comparison of the in vivo activity of IDAC-1, IDAC-3, 
Ac-PLP-cIBR1-NH2, and PBS in the mouse EAE model using incidence of disease. 
After immunization with PLP peptide in CFA, the mice received i.v. injections of 26 
nmol/injection/day of IDAC-1 or IDAC-3 on days 4 and 7. For the 
Ac-PLP-cIBR1-NH2 treatment group, the mice received i.v. injections of 50 
nmol/injection/day of the peptide on days 4, 7, and 10. For the control mice, they were 
treated with PBS on days 4, 7, and 10. There were delays in disease incidence in 
IDAC-1- and IDAC-3-treated animals.  
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conclude whether s.c. administration is better than i.v. administration in the absence of a 
direct comparison. Our previous studies indicated that s.c. administration of BPI 
molecules was more effective than i.v. administration.13 Second, the efficacy of IDAC-3 
upon vaccine-like administrations was evaluated in different doses to determine the 
therapeutic index of the molecule. In this case, the mice received s.c. injections of two 
different doses of IDAC-3 (26 nmol/injection and 10 nmol/injection), 
Ac-PLP-BPI-NH2-2 (100 nmol/injection), and PBS at 11, 8, and 5 days prior to the 
induction of the disease at day 0. Ac-PLP-BPI-NH2-2, as positive control, significantly 
suppressed EAE compared to PBS as reflected in the clinical scores (Fig. 2.4A; p < 0.005, 
days 12–17) and change in body weight (Fig. 2.4B; p < 0.005, days 12–24). Although it 
was less potent than Ac-PLP-BPI-NH2-2, mice treated with a low dose of IDAC-3 (10 
nmol/injection) had significantly better clinical scores (Fig. 2.4A, p < 0.005, days 12–17) 
and body weight changes (Fig. 2.4B; p < 0.005 through days 12–24). At a high dose (26 
nmol/injection), the third injection of IDAC-3 unfortunately caused a toxic effect in two 
of six mice; thus, the efficacy data were representative of four animals (Fig. 2.4). 
Although the statistical analysis was not carried out due to the lower number of animals, 
a high dose (26 nmol/injection) of IDAC-3 seemed to be better than the lower dose (10 
nmol/injection) group and similar to the Ac-PLP-BPI-NH2-2-treated group. IDAC-3 
effectively suppressed the disease when given in a vaccine-like schedule, and this study 
provided us with an estimated therapeutic window of IDAC-3 with a maximum toxic 
concentration of 3 injections of IDAC-3 at 26 nmol and a minimum effective 
concentration of 3 injections of 10 nmol. Finally, the best efficacy of IDAC-3 was found 
when using s.c. injections of IDAC-3 on days 4 and 7.  
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Figure 2.4A Comparison of the in vivo activity of IDAC-3, Ac-PLP-LABL-NH2-2, 
and PBS in the mouse EAE model using clinical disease scores. After immunization 
with PLP peptide in CFA, the mice received subcutaneous injections of either 10 
nmol/injection/day or 26 nmol/injection/day of IDAC-3 on days -11, -8, and -5. Mice 
also received s.c. injections of 26 nmol/injection/day of IDAC-3 on days 4 and 7. For 
the Ac-PLP-LABL-NH2-2 treatment group, the mice received s.c. injections of 100 
nmol/injection/day of the peptide on days -11, -8, and -5. The control mice were 
treated with s.c. injections of PBS on days -11, -8 ,and -5. IDAC-3 injected s.c. (26 
nmol/injection) on days 4 and 7 was significantly more efficacious than PBS in 
suppressing EAE (p < 0.005, through days 12–17). Ac-PLP-BPI-NH2-2 significantly 
suppressed EAE compared to PBS (p < 0.005, days 12–17). Mice treated with a low 
dose of IDAC-3 (10 nmol/injection) had significantly better clinical scores than PBS 
(p < 0.005, days 12–17). The results are expressed as the mean ± S.E. (n ≥ 6).  
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Figure 2.4B Comparison of the in vivo activity of IDAC-3, Ac-PLP-LABL-NH2-2, 
and PBS in the mouse EAE model using change in body weight. After immunization 
with PLP peptide in CFA, the mice received subcutaneous injections of either 10 
nmol/injection/day or 26 nmol/injection/day of IDAC-3 on days -11, -8, and -5. Mice 
also received s.c. injections of 26 nmol/injection/day of IDAC-3 on days 4 and 7. For 
the Ac-PLP-LABL-NH2-2 treatment group, the mice received s.c. injections of 100 
nmol/injection/day of the peptide on days -11, -8, and -5. The control mice were 
treated with s.c. injections of PBS on days -11, -8 ,and -5. IDAC-3 injected s.c. (26 
nmol/injection) on days 4 and 7 was significantly more efficacious than PBS in 
suppressing EAE (p < 0.005, through days 12–24). Ac-PLP-BPI-NH2-2 significantly 
suppressed EAE compared to PBS (p < 0.005, days 12–24). Mice treated with a low 
dose of IDAC-3 (10 nmol/injection) lost significantly less weight than PBS (p < 0.005 
through days 12–24). The results are expressed as the mean ± S.E. (n ≥ 6). 
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Figure 2.4C Comparison of the in vivo activity of IDAC-3, Ac-PLP-LABL-NH2-2, 
and PBS in the mouse EAE model using incidence of disease. After immunization 
with PLP peptide in CFA, the mice received subcutaneous injections of either 10 
nmol/injection/day or 26 nmol/injection/day of IDAC-3 on days -11, -8, and -5. Mice 
also received s.c. injections of 26 nmol/injection/day of IDAC-3 on days 4 and 7. For 
the Ac-PLP-LABL-NH2-2 treatment group, the mice received s.c. injections of 100 
nmol/injection/day of the peptide on days -11, -8, and -5. The control mice were 
treated with s.c. injections of PBS on days -11, -8 ,and -5. All treatment groups 
delayed the onset of disease. Compared to PBS, the percent of mice that were EAE-
free were greater in the IDAC-treated groups. 
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 To test the optimal concentration for vaccine-like delivery and its long-term effect 
in suppressing relapse, IDAC-3 was injected twice via the s.c. route (26 nmol/injection on 
days -11 and -8) and was compared to three s.c. injections of Ac-PLP-BPI-NH2-2 (100 
nmol/injection; days -11, -8, and -5), and PBS (days -11, -8, -5). Two injections of 
IDAC-3 (26 nmol) clearly suppressed EAE significantly better than PBS and had a long-
term effect in suppressing relapse of the disease as indicated in the clinical scores (Fig. 
2.5A, p < 0.0001, days 12–17, and days 45–55) and change of body weight (Fig. 2.5B, p 
< 0.0001, days 12–24). Similarly, Ac-PLP-BPI-NH2-2 had a long-term effect to prevent 
relapse. Delay in the onset of disease was observed in both treatment groups (Fig. 2.5C). 
 
2.3.3 Cytokine Levels in SJL/J Mice In Vitro 
 The potential mechanism of action of IDAC-3 was elucidated by comparing the 
cytokine levels (i.e., IL-2, IL-5, IL-10, IL-12, and IL-17) in splenocytes after two s.c. 
injections of IDAC-3 (26 nmol/injection) and PBS on days 4 and 7.  The levels of 
cytokines were determined during the peak of disease on day 13 and after EAE went into 
remission and plateaued on day 35 (Fig. 2.6). Due to the low detection limit or the lack of 
statistical significance between IDAC-3 and PBS treatment, the levels of IL-4, IL-6, and 
IFNγ were inconclusive. One of the most exciting findings was that the IDAC-3-treated 
animals had fourfold lower IL-17 during the disease remission on day 35 compared to the 
PBS-treated group (Fig. 2.6A, p < 0.0001).  
In the PBS-treated group, IL-2 cytokine levels were higher than in the IDAC-3-
treated group on day 13 (p < 0.05) whereas no significant difference was observed on day 
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Figure 2.5A Comparison of the in vivo activity of IDAC-3, Ac-PLP-BPI-NH2-2, and 
PBS in the mouse EAE model using clinical disease scores. After immunization with 
PLP peptide in CFA, the mice received vaccine-like s.c. injections of 26 
nmol/injection/day of IDAC-3 on days -11 and -8. For the Ac-PLP-BPI-NH2-2 
treatment group, the mice received s.c. injections of 100 nmol/injection/day of the 
peptide on days -11, -8, and -5. The control mice were treated with PBS on 
days -11, -8, and -5. IDAC-3 suppressed EAE significantly better than PBS and had a 
long-term effect in suppressing relapse of the disease (p < 0.0001, days 12–17, and 
days 45–55). The results are expressed as the mean ± S.E. (n ≥ 6).  
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Figure 2.5B Comparison of the in vivo activity of IDAC-3, Ac-PLP-BPI-NH2-2, and 
PBS in the mouse EAE model using change in body weight. After immunization with 
PLP peptide in CFA, the mice received vaccine-like s.c. injections of 26 
nmol/injection/day of IDAC-3 on days -11 and -8. For the Ac-PLP-BPI-NH2-2 
treatment group, the mice received s.c. injections of 100 nmol/injection/day of the 
peptide on days -11, -8, and -5. The control mice were treated with PBS on 
days -11, -8, and -5. IDAC-3 suppressed EAE significantly better than PBS (p < 
0.0001, days 12–24). The results are expressed as the mean ± S.E. (n ≥ 6).  
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Figure 2.5C Comparison of the in vivo activity of IDAC-3, Ac-PLP-BPI-NH2-2, and 
PBS in the mouse EAE model by incidence of disease. After immunization with PLP 
peptide in CFA, the mice received vaccine-like s.c. injections of 26 nmol/injection/day 
of IDAC-3 on days -11 and -8. For the Ac-PLP-BPI-NH2-2 treatment group, the mice 
received s.c. injections of 100 nmol/injection/day of the peptide on days -11, -8, 
and -5. The control mice were treated with PBS on days -11, -8, and -5. Both 
treatment groups delayed the onset of disease compared to PBS. Compared to PBS, 
the percent of mice that were EAE-free were greater in both of the treatment groups. 
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35 (Fig. 2.6B). Although there was no significant difference in IL-5 levels on day 13, the 
IL-5 levels on day 35 were significantly higher in the IDAC-3-treated group than in the 
PBS-treated group (Fig. 2.6C, p < 0.0005). The cytokine levels of IL-10 on day 13 could 
not be detected; however, once the disease remission plateaued on day 35, the IDAC-3-
treated group had significantly higher levels of IL-10 compared to the PBS group (Fig. 
2.6D, p < 0.05). In the IDAC-3-treated group, the level of IL-12 was significantly lower 
than in the PBS-treated group on day 35 (Fig. 2.6E, p < 0.005).  
 
2.4 DISCUSSION 
The I-domain emerged as a useful carrier protein to target antigenic peptides to 
suppress EAE. Previously, peptides derived from the I-domain, namely LABL 
(CD11a237-246), had been conjugated to immunodominant antigenic peptides to suppress 
various autoimmune diseases in animal models of EAE, type-1 diabetes, and rheumatoid 
arthritis.7,8,10 In these studies, LABL was conjugated to a single antigenic peptide (i.e., 
PLP, collagen-II, or GAD peptide). In the current study, the I-domain lysine residues 
were conjugated with multiple peptides from a single epitope (PLP139-151). This approach 
would allow simultaneous delivery of multiple epitopes of PLP, as well as a mixture of 
epitopes from the proteolipid protein, myelin oligodendrocyte glycoprotein (MOG), and 
myelin basic protein (MBP). Another advantage of I-domain over LABL is that the 
I-domain contains the metal-ion dependent adhesion site (MIDAS) necessary for divalent 
cation coordination (Ca2+, Mg2+, or Mn2+) to enhance binding 
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Figure 2.6A IL-17 levels (days 13 and 35) from splenocytes of mice treated 
subcutaneously with PBS and IDAC-3 (26 nmol on days 4 and 7). IDAC-3-treated 
animals had lower IL-17 during the disease remission on day 35 compared to the PBS-
treated group (p < 0.0001). 
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Figure 2.6B IL-2 levels (days 13 and 35) from splenocytes of mice treated 
subcutaneously with PBS and IDAC-3 (26 nmol on days 4 and 7). In the PBS-treated 
group, IL-2 cytokine levels were higher than in the IDAC-3-treated group on day 13 (p 
< 0.05). 
 
 60 
Figure 2.6C IL-5 levels (days 13 and 35) from splenocytes of mice treated 
subcutaneously with PBS and IDAC-3 (26 nmol on days 4 and 7). IL-5 levels on day 
35 were significantly higher in the IDAC-3-treated group than in the PBS-treated 
group (p < 0.0005). 
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Figure 2.6D IL-10 levels (days 13 and 35) from splenocytes of mice treated 
subcutaneously with PBS and IDAC-3 (26 nmol on days 4 and 7). The IDAC-3-
treated group had significantly higher levels of IL-10 compared to the PBS group (p < 
0.05). 
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Figure 2.6E IL-12 levels (days 13 and 35) from splenocytes of mice treated 
subcutaneously with PBS and IDAC-3 (26 nmol on days 4 and 7). In the IDAC-3-
treated group, the level of IL-12 was significantly lower than in the PBS-treated group 
on day 35 (p < 0.005). 
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selectivity to ICAM-1 on the cell surface.14 The expression of ICAM-1 is increased on 
cell surfaces in autoimmune diseases as well as in other diseases.15,16 
Our current findings suggested that two injections (26 nmol/injection) of IDAC-3 
with capped PLP peptide could suppress disease severity more efficiently than IDAC-1 
with the uncapped PLP peptide. This corroborates a similar finding from our previous 
study in which capped Ac-PLP-BPI-NH2-2 peptide could suppress EAE better than its 
uncapped counterpart (PLP-BPI).7 These results suggested that capped PLP peptide 
might have higher metabolic stability than the uncapped peptide; in other words, the 
uncapped peptide is prone to exopeptidases (i.e., amino- and carboxy-peptidases). 
Because SDS-PAGE, CD, and mass spectrometry analyses suggest that IDAC-1 and 
IDAC-3 are very similar, it is plausible that the major difference in their in vivo activity is 
due to the improved metabolic stability of the peptide and not due to the different 
conformation of the molecule. 
IDAC-3 dosed subcutaneously on days 4 and 7 was very effective in suppressing 
EAE. One advantage of subcutaneous dosing is that IDAC molecules may drain into the 
lymph nodes to modulate immune cells.17,18 The administration of IDAC-3 prior to the 
induction of disease had a significant long-term effect in suppressing disease relapse after 
55 days compared to PBS, suggesting that IDAC-3 works by tipping the balance of the 
immune cells from inflammatory to regulatory phenotypes. It also suggested that vaccine-
like delivery could alter the balance of the immune cells to regulatory cells prior to the 
stimulation of the disease. However, IDAC-3 had a narrow therapeutic index because the 
third injection of 26 nmol of IDAC-3 on day -5 in vaccine-like delivery caused adverse 
events in 2 of the 6 mice.  A lower dose of vaccine-like subcutaneous injections of 10 
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nmol on days -11, -8, and -5 in a separate group did not result in anaphylaxis, but was not 
as effective as the 26 nmol dose. As controls, I-domain and the GMB-I-domain had slight 
delays of disease onset, but no significant suppression of disease; this activity was 
probably due to the general inhibition of LFA-1/ICAM-1-mediated leukocyte adhesion.11 
Thus, the effect of injections of IDAC-3 and I-domain on the differentiation of immune 
cells will be evaluated in the future. In addition, the effect of increasing the dose while 
maintaining the schedule of 2 injections as well as multiple injections (greater than 3 
injections) at low doses (less than 10 nmol) by spreading the injection over a larger 
timespan will also be investigated.  
During the peak severity of the disease on day 13, splenocytes isolated from the 
mice treated with PBS and IDAC-3 had similar levels of IL-17 production. However, on 
day 35, IDAC-3-treated mice were found to have significantly lower levels of IL-17 
compared to the PBS group, indicating that IDAC-3 has long-term effects in suppressing 
EAE. Th17 is a major T cell found to play a large role in the pathogenesis of both EAE 
and MS.5,19-22 Significant suppression of disease, coupled with lower levels of IL-17 on 
day 35, suggested that two injections of IDAC-3 suppressed the disease by modulating 
the immune system of the mice and shifting the response from an inflammatory to a 
regulatory phenotype. The higher level of IL-17 on day 35 in the mouse group treated 
with PBS may suggest an impending relapse of disease. This correlated with our previous 
observations in mice treated with Ac-PLP-BPI-NH2-2, suggesting the involvement of 
regulatory cells and the downregulation of Th17.7,9 
While IL-10 levels were below detection limits on day 13, higher levels of IL-10 
production were observed in mice treated with IDAC-3 compared to PBS on day 35, 
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indicating the potential involvement of T-reg cells. Previously, BPI-treated animals also 
produced IL-10 cytokine.8 In addition, IDAC-3 induced IL-5, indicating the involvement 
of Th2 phenotype. A shift away from a Th1-response was observed from the involvement 
of lower levels of IL-2 in the IDAC-3-treated group compared to the PBS-treated mice. 
Furthermore, the lower levels of IL-12 in the IDAC-3-treated compared to PBS-treated 
mice imply that the IDAC-3 induced the differentiation away from a Th1-mediated 
response to a non-immunogenic response. 
The potential mechanisms of action of IDAC-3 could be due to the delivery of the 
antigenic peptide to APC to alter the differentiation of naïve T cells to regulatory T cells 
and suppress the proliferation of inflammatory Th17 and Th1. As in BPI molecules, 
IDAC-3 could bind simultaneously to ICAM-1 and MHC-II to inhibit the formation of 
the immunological synapse at the interface between T cells and APC. By inhibiting the 
formation of the immunological synapse, the differentiation of T cells was shifted from 
inflammatory to immune-regulatory response. Previously, it was found that a BPI 
molecule (GAD-BPI) that suppressed type I diabetes could simultaneously bind to 
MHC-II and ICAM-1 and co-localize them on the surface of B cells isolated from the 
non-obese diabetic (NOD) mouse.10  
Another possible mechanism by which IDAC could work is that the I-domain 
binds to ICAM-1 and the conjugate is internalized.11,23 Previous studies had shown that 
the I-domain conjugated to fluorophores at the Lys residues could effectively bind to 
ICAM-1 and enter leukocytes by receptor-mediated endocytosis despite having a 
heterogeneous mixture.11,24 The proposed mechanism is that IDAC-3 binds to ICAM-1 
and suppresses the adequate leukocyte adhesion necessary to form a steady T cell:APC 
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contact. Once IDAC-3 is internalized into the APC cytoplasm, PLP is loaded onto the 
MHC-II in the Golgi apparatus and is transported to the cell surface for presentation, 
while the internalized ICAM-1 disappears from the cell surface.23 Therefore, at the time 
the PLP-MHC-II-complex is presented at the surface of APC, the second signal 
(ICAM-1:LFA-1) necessary for T cell activation is absent, leading to T-reg 
differentiation.25,26 However, the internalized ICAM-1 has been shown to recycle and 
resurface and, therefore, the absence of the second signal is transient.23 Along the same 
line, another proposed mechanism is that IDAC-3, in the intracellular domain prior to 
recycling to the surface, could bind with empty MHC-II to form a complex of 
MHC-II/IDAC-3/ICAM-1 followed by presentation to the surface in a co-localized 
fashion. This co-localization prevents the formation of the immunological synapse. The 
efficacy of IDAC has been confirmed and now studies may be carried out to elucidate the 
potential mechanisms of action of IDAC molecules.  
IDAC-3 is a mixture of conjugation products in which several lysine residues are 
conjugated with PLP peptide. The conditions of conjugation reaction have been 
optimized to maintain batch-to-batch reproducibility, as determined by mass 
spectrometry and CD. Using tryptic digest and mass spectrometry the sites of peptide 
conjugation were determined and the number of conjugations was found to be between 
one and five peptides per I-domain. Because IDAC-3 is a mixture, it is possible that not 
all of the conjugated products have biological activity to suppress EAE. In the future, 
several individual lysine residues will be mutated to cysteine residues (Cys-I-domain) for 
selective conjugation of peptides to a selected cysteine residue. It should be noted that the 
I-domain does not contain any cysteine residues. Thus, the resulting conjugate will be a 
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single conjugate instead of a mixture of conjugates. Then, the efficacy of each conjugated 
product may be evaluated in the EAE mouse model. This study will provide us with the 
important conjugation site(s) in the I-domain that produce biological activity.  
 
2.5 CONCLUSIONS 
In conclusion, IDAC-3 effectively inhibited the onset and severity of EAE in mice. 
The conjugation of multiple copies of a single antigenic epitope to the I-domain of LFA-1 
suppressed EAE by shifting the immune response to a regulatory phenotype. IDAC-3 
also suppressed the relapse of EAE when delivered in a vaccine-like manner. Cytokine 
studies suggested that IDAC-3 suppressed disease by shifting the immune balance away 
from Th17-mediate pathology by increasing involvement of T-reg. Further studies using 
IDAC will involve optimizing the dose and the dosing strategy to lower toxicity and 
improve efficacy. Finally, the effect of epitope spreading will be addressed by 
conjugating other immunodominant epitopes, such as MOG and MBP, to the I-domain.  
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CHAPTER 3 
Vaccine-like controlled-release delivery of an immunomodulating peptide to treat 
experimental autoimmune encephalomyelitis 
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3.1 INTRODUCTION 
During the course of multiple sclerosis (MS), the myelin sheath surrounding the 
nerves becomes demyelinated, exposing multiple proteins that are processed and 
presented on the surface of antigen-presenting cells (APC).1 The immunodominant 
epitopes from the myelin sheath that are presented on the surface of major 
histocompatibility complex class II (MHC-II) include the proteolipid protein (PLP), 
myelin oligodendrocyte glycoprotein (MOG), and myelin basic protein (MBP).2 
Modulating the immune response is the goal of many of the available therapies for MS.3 
Many of the current treatments fall short because they suppress the general immune 
system.4 In contrast, bifunctional peptide inhibitors (BPI) are molecules that provide a 
more selective approach in modulating the immune response by modifying the response 
of a sub-population of T cells. BPI is a peptide complex in which two functional peptides 
are tethered together by a linker. The hypothesis is that the antigenic peptide and the 
adhesion peptide of the BPI simultaneously bind to MHC-II and ICAM-1 on the surface 
of antigen-presenting cells (APC) suppressing the translocation of signal-1 (MHC-II:T 
cell interaction) and signal-2 (ICAM-1:LFA-1 interaction) molecules necessary for the 
formation of the immunological synapse, thereby suppressing T cell activation.5,6  
PLP-BPI molecule has been shown to suppress experimental autoimmune 
encephalomyelitis (EAE) in the mouse model when injected three times in solution in a 
vaccine-like manner 11, 8, and 5 days prior to disease stimulation. Although we have had 
success with this treatment in suppressing EAE, translating this into a human model must 
be simplified. Studies have shown that compliance is an important factor in achieving 
success in multi-dose vaccinations.7 A one-time injection is ideal for achieving a higher 
 74 
degree of compliance. Therefore, it will be beneficial if PLP-BPI can be delivered in a 
controlled-release manner using a one-time injection. Previously, there have been very 
few successful applications of protein and peptide controlled-release therapies.13,14 
Because nanoparticles containing alginate and chitosan have been shown to be effective 
for delivering protein antigen and can stabilize ovalbumin, we decided to utilize these 
polysaccharides to deliver a therapeutic peptide to suppress EAE.15 
Poly(D,L-lactic-co-glycolic acid) (PLGA) is a well-established biocompatible and 
biodegradable polymer.16 Therefore, chitosan and alginate, along with PLGA, were used 
to deliver PLP-BPI for treating EAE in a vaccine-like manner.  
Here, a PLP-BPI molecule called Ac-PLP-BPI-NH2 was formulated into alginate-
PLGA/chitosan-PLGA colloidal gels for the controlled-release delivery of peptide in a 
vaccine-like manner. In this study, the efficacy of Ac-PLP-BPI-NH2 released from 
colloidal gel to suppress EAE after a single injection was evaluated, and its long-term 
effect in suppressing EAE was also monitored. The results indicated that vaccine-like 
injection of Ac-PLP-BPI-NH2-2 in colloidal gel was very effective in suppressing EAE as 
well as the relapse of EAE in the mouse model. The mechanism of suppression was due 
to the shift in the immune response away from Th17-mediated pathology of EAE. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
PLGA (50:50) (Polymer Type: 5050 DLG 2A, inherent viscosity: 0.15–0.25 dl/g) 
was purchased from Lakeshore Biomaterials (Birmingham, AL). Low molecular weight 
chitosan was purchased from Sigma Aldrich Co. (St. Louis, MO) (448869, degree of 
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deacetylation: 75%–85%, Brookfield viscosity: 20–200 cps). Sodium alginate (Mv = 1.6 
× 105, dynamic viscosity was 39 MPa·s in a 1.0% solution at 20 oC) was obtained from 
FMC BioPolymer (Philadelphia, PA). 	  
 
3.2.2 Animals 
 The female SJL/J mice used in this study were purchased from Charles River 
Laboratories, Inc. (Wilmington, MA) and were housed under specific pathogen-free 
conditions at the animal facility at The University of Kansas approved by the Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All 
experimental procedures used in this study were approved protocols reviewed by the 
Institutional Animal Care and Use Committee (IACUC) at The University of Kansas. 
 
3.2.3 Peptide Synthesis 
 PLP (NH2-HSLGKWLGHPDKF-OH) and Ac-PLP-BPI-NH2-2 
(Ac-HSLGKWLGHPDKF-(AcpGAcpGAcp)2-ITDGEATDSG-NH2 (Ac = acetyl, Acp = 
aminocaproic acid)) were synthesized using a 9-fluorenylmethyloxycarbonyl- (FMOC) 
protected solid-phase peptide chemistry on appropriate polyethylene glycol-polystyrene 
resins on an automated peptide synthesizer (Pioneer; Perceptive Biosystems, Framingham, 
MA). Trifluoroacetic acid (TFA) with scavengers was used to remove the amino acid 
protecting groups as well as the peptides from the resin. A semi-preparative reversed-
phase high-performance liquid chromatography (RP-HPLC) with a C18 column was used 
to purify the crude peptides. A gradient method was used for purification with solvent A 
(94.9% water, 5% acetonitrile, and 0.1% trifluoroacetic acid) and solvent B (100% 
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acetonitrile). The purity of the peptide was analyzed by analytical RP-HPLC using a C18 
column (purity > 96%). The identity of the peptides was confirmed using matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. 
 
3.2.4 Preparation of Charged PLGA Nanoparticles 
 Oppositely charged blank PLGA nanoparticles were prepared by a solvent 
diffusion method. 150 mg of PLGA was dissolved in 10 ml of acetone and then the 
solution was added into 0.2% of either alginate or chitosan (150 ml) surfactant solution 
through a syringe pump at a constant rate of 30 ml/h under stirring at 200 rpm. The 
resulting solution was stirred overnight to evaporate the acetone. Nanoparticles were then 
centrifuged (10,000 rpm) for 30 min and the resulting PLGA pellet was resuspended in 
double-distilled water and washed three times to remove excess surfactant. The final 
resuspended product was then lyophilized for two days.  
 
3.2.5 Preparation of Peptide-loaded Colloidal Gels 
 Lyophilized nanoparticles (PLGA-alginate or PLGA-chitosan) were dispersed in 
deionized water at 20% weight/volume followed by mixing of the two dispersions in a 
1:1 ratio; then, the mixture was sonicated for 3 minutes to prepare a homogenous colloid 
mixture. Immediately before injecting into mice, Ac-PLP-BPI-NH2-2 peptide was 
physically mixed for 2 min with the colloidal gel in a 1:10 ratio of peptide to PLGA. 
 
3.2.6 Characterization of Nanoparticles and Colloidal Gels 
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 The zeta potentials and the sizes of PLGA-alginate and PLGA-chitosan 
nanoparticles were determined in triplicate using dynamic light scattering (Brookhaven, 
ZetaPALS). Scanning electron microscopy (SEM) was performed using a Leo 1550 field 
emission scanning electron microscope at an accelerating voltage of 5 kV. 
 
3.2.7 In Vitro Peptide Release from Colloidal Gel 
 Peptide release from colloidal gel formulation was measured fluorometrically at 
excitation λ=280 nm and emission λ=350 nm with a Shimadzu RF5000U 
spectrofluorophotometer (Shimadzu Co., Kyoto, Japan). Colloidal gel samples containing 
Ac-PLP-BPI-NH2-2 (n = 3) were placed in a sealed 1.5 ml buffered solution (PBS, pH 
7.4) and stirred at 50 rpm at 37 °C. Samples containing the peptide were removed at 
different time points after centrifugation and replaced with fresh buffer. The 
concentrations of the peptide were determined using fluorescence spectroscopy as 
described above.  
 
3.2.8 Induction of EAE and Efficacy Evaluations 
 Six-to-eight week old mice were immunized subcutaneously (s.c.) on day 0 with 
200 µg PLP139-151 peptide in a 0.2 ml emulsion consisting of equal volumes of PBS and 
complete Freund’s adjuvant (CFA) containing killed mycobacterium tuberculosis strain 
H37RA (at a final concentration of 4 mg/ml, Difco, Detroit, MI) to induce disease. The 
emulsion of PLP/CFA was administered to the regions above the shoulder and the flanks 
(50 µl at each injection site, for a total of 4 injections). Additionally, 200 ng of pertussis 
toxin was administered intraperitoneally on days 0 and 2. 
 78 
 As a positive control, mice received three s.c. injections of Ac-PLP-BPI-NH2-2 in 
PBS (100 nmol/injection) at 11, 8, and 5 days prior to stimulation of the disease on day 0. 
Then, Ac-PLP-BPI-NH2-2 (300 nmol) in colloidal gel (Ac-PLP-BPI-NH2-2-NP) was 
injected once via the s.c. route 5 days before induction of the disease on day 0. To 
determine the effects of the timing of the dose, a different group of mice was treated with 
one s.c. injection of Ac-PLP-BPI-NH2-2-NP at day 4 after disease stimulation on day 0. 
To determine the ability of the Ac-PLP-BPI-NH2-2-NP treatment to suppress the relapse 
of EAE, another group was treated on day 30, after the disease went into remission. As 
negative controls, two different groups of mice received either PBS on days -11, -8, 
and -5, or blank colloidal gel (blank-NP) on day -5 prior to disease induction. 
Disease progression was evaluated by observing the change in body weight of the 
mice and clinical scoring: 0—no clinical symptoms of disease; 1—tail weakness or limp 
tail; 2—paraparesis (weakness or partial paralysis of one or two hind limbs); 3—
paraplegia (complete paralysis of two hind limbs); 4—paraplegia with forelimb weakness 
or paralysis; 5—moribund. When the mice were found to be moribund, they were 
promptly euthanized. 
 
3.2.9 Determination of Cytokine Levels In Vitro 
Spleens from representative mice treated with Ac-PLP-BPI-NH2-2, 
Ac-PLP-BPI-NH2-2-NP, and blank-NP were isolated during the peak of the relapse, on 
day 55. The spleen was gently smashed using the coarse end of a 1 ml syringe in a petri 
dish containing RPMI 1640 medium (10% FBS, 0.05 M BME) to yield the splenocytes of 
interest. The splenocytes were then filtered through a nylon 40 micrometer strainer. After 
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centrifugation, “ACK lysis buffer” containing 0.15 M NH4Cl, 10 mM KHCO3, and 0.1 
mM EDTA was used to lyse the red blood cells followed by washing of the remaining 
white blood cells with medium. 5 × 106 splenocytes/ml were cultured in parallel in the 
presence of 20 µM PLP and blank RPMI medium. Supernatants were collected at a 72 h 
time-point for the measurement of cytokine levels and stored at -80 °C until analysis. The 
samples were then analyzed using a fully quantitative ELISA-based Q-PlexTM Mouse 
Cytokine-Screen (Quansys Biosciences, Logan, UT). 
 
3.2.10 Statistical Analysis 
Statistical differences among the groups in clinical disease scores were 
determined by calculating the average score for each mouse from day 12 to day 17, or 
from day 45 to day 55 by one-way analysis of variance followed by Fisher’s least 
significant difference.  Statistical differences in body weight among groups were also 
analyzed in the same fashion, but from day 12 to day 24. Comparison of cytokine 
concentrations was also performed by one-way analysis of variance. All analyses were 
performed using StatView (SAS Institute, Cary, NC). 
 
3.3 RESULTS 
3.3.1 Characterization of Coated Nanoparticles and Colloidal Gel 
Coated nanoparticles were prepared by a solvent diffusion method where PLGA 
in acetone was titrated into an alginate- or chitosan-containing water phase. Once in the 
water phase, PLGA was precipitated and coated with either a negatively charged 
(alginate) or a positively charged (chitosan) polysaccharide. Mixing these two particle 
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Figure 3.1: Scheme of positively and negatively charged PLGA nanoparticle 
fabrication to form peptide-loaded colloidal gel. 
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A) 
 
B) 
 
 
Figure 3.2: Scanning electron micrographs of (A) blank colloidal gel, and (B) 
Ac-PLP-BPI-NH2-2-loaded colloidal gel. Scale bar is 1 µm. 
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types together leads to the self-assembly of dense colloidal gels (Fig. 3.1).  The size of 
the chitosan-PLGA was 400.1±13.9 nm (polydispersity = 0.092), whereas the alginate-
PLGA size was 208.1±7.6 nm (polydispersity = 0.111). The zeta potentials of alginate-
PLGA and chitosan-PLGA were found to be -38.85±1.54 mV and 23.79±2.16 mV, 
respectively. Using scanning electron microscopy, no differences were observed between 
the structure of the dried blank colloidal gel and dried Ac-PLP-BPI-NH2-2-loaded 
colloidal gel (Fig. 3.2A and 3.2B). Both images suggested a tightly packed colloidal gel 
formed by the interacting chitosan-alginate nanoparticles. 
 
3.3.2 In Vitro Peptide Release from Colloidal Gel 
 The in vitro peptide release into PBS medium from colloidal gels was measured 
by detection of fluorescence emission of the tryptophan and phenylalanine side chains in 
Ac-PLP-BPI-NH2-2 (Fig. 3.3). Initially, approximately 24% of the peptide was released 
within the first two hours; this was most likely due to the rapid release of peptide from 
the surface of the colloidal gel. It was followed by a relatively less pronounced release 
over a period of 24 hours (~ 64%). Eventually, the amount of peptide released plateaued 
after day 1, suggesting that the remaining peptide diffused through the gel network into 
the solution.  
 
3.3.3 Efficacy of Ac-PLP-BPI-NH2-2 in Colloidal Gel for Suppression of EAE 
 Previously, EAE could be suppressed in mice by administering 
Ac-PLP-BPI-NH2-2 in buffered solution (i.v. or s.c.) on days 4, 7, and 10, or a one-time 
injection of Ac-PLP-BPI-NH2-2-loaded microparticles (s.c.) on day 4. Here, 
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Figure 3.3: In vitro release of Ac-PLP-BPI-NH2-2 from colloidal gel (in PBS 
solution, 37 oC, 50 rpm stirring). n = 3 ± S.D. 
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Ac-PLP-BPI-NH2-2-NP was used for one-time delivery of the peptide to suppress EAE. 
Three groups of mice received subcutaneous injections of the peptide-loaded colloidal gel 
(300 nmol/injection) on day -5, day 4, or day 30 (Fig. 3.4). The mice treated with 
Ac-PLP-BPI-NH2-2-NP five days prior to (day -5) or four days after (day 4) the induction 
of disease had significantly lower clinical scores compared to control, PBS, or blank-NP 
(p < 0.01, through days 12–17) (Fig. 3.4A). Furthermore, the changes in body weight 
were significantly less than in the control groups, suggesting that treating mice with 
Ac-PLP-BPI-NH2-2-NP prior to the onset of disease is significantly more effective than 
treatment with PBS or blank-NP in suppressing disease (p < 0.01, through days 12–24) 
(Fig. 3.4B). Although the group that received the peptide-loaded gel formulation on day 4 
got sick faster, their recovery was quicker than that of the control groups, and the amount 
of body weight lost was similar to that of the Ac-PLP-BPI-NH2-2-NP (-5) group by day 
15 (Fig. 3.4A and 3.4B). Compared to PBS and the blank colloidal gel control groups, a 
delay in the onset of disease was apparent in the mice groups treated with 
Ac-PLP-BPI-NH2-2-NP on day -5 (Fig. 3.4C).  
 When observing the long-term effect of suppressing the relapse of disease, it was 
noted that Ac-PLP-BPI-NH2-2-NP (-5) could suppress disease significantly better than 
the controls and there was no significant difference when compared to the positive 
control (p > 0.05, through days 45–55) (Fig. 3.4A). Ac-PLP-BPI-NH2-2-NP, when 
administered 4 days after the induction of disease, could suppress disease significantly 
better than the controls (p < 0.0001, through days 45–55) (Fig. 3.4A). 
 To test the efficacy of Ac-PLP-BPI-NH2-2-NP to suppress relapse, another group 
of mice was administered the peptide-loaded colloidal gel on day 30. It was observed that 
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Time (Days) 
PBS 
Ac-PLP-BPI-NH2-2 100 nmol(-11,-8,-5) 
Blank NP (-5) 
Ac-PLP-BPI-NH2-2-NP 300 nmol(-5) 
Ac-PLP-BPI-NH2-2-NP 300 nmol(4) 
Ac-PLP-BPI-NH2-2-NP 300 nmol(30) 
Figure 3.4A: Comparison of the in vivo activity of Ac-PLP-BPI-NH2-2 in solution, 
Ac-PLP-BPI-NH2-2-NP, blank colloidal gel, and PBS using clinical disease scores. In 
the controlled-release treatments, different groups of SJL/J mice received a one-time 
injection of 300 nmol peptide-gel formulation on days -5, 4, or 30. Mice were also 
treated with a one-time injection of blank colloidal gel 5 days prior to the induction of 
disease. The positive control group (Ac-PLP-BPI-NH2-2, 100 nmol/injection) was 
treated on days -11, -8, and -5. The mice group receiving PBS was also injected on 
days -11, -8, and -5. The mice treated with Ac-PLP-BPI-NH2-2-NP on day -5 and day 
4 had significantly lower clinical scores compared to negative control, PBS, or 
blank-NP (p < 0.01, through days 12–17, and p < 0.0001, through days 45–55). No 
significant difference was observed between Ac-PLP-BPI-NH2-2-NP (-5) and the 
positive control (p > 0.05, through days 45–55). No significant difference in clinical 
scores was observed when comparing the mice treated with Ac-PLP-BPI-NH2-2-NP 
on day 30 to negative controls (p > 0.05, through days 45–55). The results are 
expressed as the mean ± S.E. (n ≥ 6). 
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Figure 3.4B: Comparison of the in vivo activity of Ac-PLP-BPI-NH2-2 in solution, 
Ac-PLP-BPI-NH2-2-NP, blank colloidal gel, and PBS using change in body weight. In 
the controlled-release treatments, different groups of SJL/J mice received a one-time 
injection of 300 nmol peptide-gel formulation on days -5, 4, or 30. Mice were also 
treated with a one-time injection of blank colloidal gel 5 days prior to the induction of 
disease. The positive control group (Ac-PLP-BPI-NH2-2, 100 nmol/injection) was 
treated on days -11, -8, and -5. The mice group receiving PBS was also injected on 
days -11, -8, and -5. The mice treated with Ac-PLP-BPI-NH2-2-NP on day -5 and day 
4 had significantly less changes in body weight compared to PBS, or blank-NP (p < 
0.01, through days 12–24). The results are expressed as the mean ± S.E. (n ≥ 6). 
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Figure 3.4C: Comparison of the in vivo activity of Ac-PLP-BPI-NH2-2 in solution, 
Ac-PLP-BPI-NH2-2-NP, blank colloidal gel, and PBS using incidence of disease. In 
the controlled-release treatments, different groups of SJL/J mice received a one-time 
injection of 300 nmol peptide-gel formulation on days -5, 4, or 30. Mice were also 
treated with a one-time injection of blank colloidal gel 5 days prior to the induction of 
disease. The positive control group (Ac-PLP-BPI-NH2-2, 100 nmol/injection) was 
treated on days -11, -8, and -5. The mice group receiving PBS was also injected on 
days -11, -8, and -5. Compared to PBS and the blank colloidal gel control groups, a 
delay in the onset of disease was apparent in the mice group treated with 
Ac-PLP-BPI-NH2-2-NP on day -5. The results are expressed as the mean ± S.E. (n ≥ 
6). 
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the mice showed signs of recovery with a decreasing clinical score but, upon the time of 
the relapse of disease (after day 43), no significant difference in clinical scores was 
observed when compared to the negative controls (p > 0.05, through days 45–55) (Fig. 
3.4A). 
 
3.3.4 In Vitro Cytokine Production 
To examine the cytokines produced in response to the different treatments, 
spleens from three different groups (Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, and 
blank-NP) were isolated on day 55 and observed for their response to PLP stimulation. 
The interactions of many different cytokines are complicated, and the ability to determine 
the role for an individual cytokine is not straightforward. However, one can generalize 
cytokines into different effector groups. The cytokines that are generally produced during 
an inflammatory response include IL-6, IL-17, and IFNγ whereas the cytokines that 
induce suppressor and regulatory responses include IL-2, IL-4, and IL-5. 
Mice treated with solution Ac-PLP-BPI-NH2-2 and Ac-PLP-BPI-NH2-2-NP were 
observed to have significantly lower levels of IL-6, IL-17, and IFNγ, suggesting that both 
formulations were effectively suppressing disease by shifting the immune response away 
from Th17 production (Fig. 3.5A-C, p < 0.05). It was interesting to observe that IL-6 and 
IFNγ levels were significantly lower for the Ac-PLP-BPI-NH2-2-NP formulation group 
than the group treated with solution Ac-PLP-BPI-NH2-2 (p < 0.005). 
Compared to the blank-NP group, IL-2 levels were significantly higher for the 
Ac-PLP-BPI-NH2-2 treated mice (p < 0.05) whereas no significant difference was 
observed between the peptide-loaded gel and the blank colloidal gel (p > 0.05) (Fig. 
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Figure 3.5A: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-6 cytokine levels were significantly 
lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.005) and PBS (*, p 
< 0.05). 
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Figure 3.5B: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
In the Ac-PLP-BPI-NH2-2- and Ac-PLP-BPI-NH2-2-NP-treated groups, IL-17 
cytokine levels were significantly lower than in the group treated PBS (*, p < 0.05). 
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Figure 3.5C: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
In the Ac-PLP-BPI-NH2-2-NP-treated group, IFNγ cytokine levels were significantly 
lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.005) and PBS (*, p 
< 0.05). 
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Figure 3.5D: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-2 cytokine levels were significantly 
lower than in the group treated with Ac-PLP-BPI-NH2-2 (#, p < 0.0005). On the other 
hand, IL-2 production was higher in the Ac-PLP-BPI-NH2-2-treated group than in the 
negative control (p < 0.05). 
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Figure 3.5E: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
No significant difference in IL-4 production was observed between any of the groups 
(p > 0.05). 
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Figure 3.5F: Cytokine levels (day 55) from splenocytes of mice treated 
subcutaneously with solution Ac-PLP-BPI-NH2-2, Ac-PLP-BPI-NH2-2-NP, or PBS. 
In the Ac-PLP-BPI-NH2-2-NP-treated group, IL-5 cytokine levels were significantly 
lower than in the groups treated with Ac-PLP-BPI-NH2-2 (#, p < 0.0005) and PBS (*, 
p < 0.0005). 
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3.5D). When comparing the two treatment groups, significant differences in IL-2 
production were observed (p < 0.0005) (Fig. 3.5D). No significant difference in IL-4 
production was observed between any of the groups on day 55 (Fig. 3.5E). Whereas no 
significant difference between Ac-PLP-BPI-NH2-2 and blank-NP control groups was 
observed, IL-5 levels were significantly lower for the Ac-PLP-BPI-NH2-2-NP group (p < 
0.0005) (Fig. 3.5F). 
 
3.4 DISCUSSION 
 Previously, BPI molecules such as PLP-BPI, GAD-BPI, and CII-BPI have been 
shown to suppress the progression of autoimmune diseases in the animal models of 
diseases such as MS, type 1 diabetes, and rheumatoid arthritis, respectively.6,17-20 
Furthermore, GAD-BPI was found to simultaneously bind to MHC-II and ICAM-1, co-
localizing them on the surface of B cells that were isolated from a non-obese diabetic 
(NOD) mouse.6 It is proposed that blocking the formation of the immunological synapse 
that is necessary for T-cell activation will alter the immune response toward a regulatory 
and suppressor phenotype and away from a Th17 and/or Th1 inflammatory response.  
There are two parameters of colloidal gel to consider in delivering 
Ac-PLP-BPI-NH2-2 in a controlled-release manner; these parameters are the particle size 
and zeta potential.21 The particles were manufactured to a size of approximately 200–400 
nm because the small size allowed a stronger cohesiveness of the colloidal gel.21 For 
larger particles (in the µm range), the number of particle-particle contacts decreases, thus 
leading to a less stable colloidal gel. The large zeta potential of the coated nanoparticles 
also yields stronger electrostatic interactions, leading to tighter packing of the colloidal 
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gel. Using SEM, the formation of a tight network structure of the colloidal gel was 
observed, which suggested that oppositely charged particles are interacting and forming 
ring-like structures.22 Grooves and pores are also observed, which further suggested that 
there is also a repulsive force among similarly charged nanoparticles.22 
In vitro studies showed that Ac-PLP-BPI-NH2-2 could be delivered in a 
controlled-release manner, where the full dose was delivered in a period of a little over a 
week. One advantage of using a controlled-release system over the traditional dosing 
method is that Ac-PLP-BPI-NH2-2 was being continually released, permitting a persistent 
exposure of the peptide to APC, whereas the control method required three separate 
injections, delivering bolus doses at every injection. In another study, a hepatitis B 
vaccine that required three injections was delivered effectively using one injection in an 
alginate-chitosan microsphere formulation to produce a robust immune response.23  
Another advantage of using the colloidal gel system was the ease of formulating 
the peptide by simple mixing without losing peptide. To improve the release profile, such 
as slowing the release of the peptide, future studies will be done where the colloidal gel 
will be formulated to have higher amounts of positively charged PLGA nanoparticles to 
improve electrostatic adsorption,24 due to the net charge of -2 for Ac-PLP-BPI-NH2-2. 
Peptide release may also be delayed or increased by adjusting the loading. 
Vaccine-like delivery of Ac-PLP-BPI-NH2-2 (day -5) from the colloidal gel was 
shown to be effective in suppressing disease throughout the study, including relapse. 
Administration of Ac-PLP-BPI-NH2-2 after the induction of disease on day 4 was able to 
suppress disease better than the controls during both the initial phase of the disease and 
the relapse. However, administration of Ac-PLP-BPI-NH2-2-NP on day 4 did not 
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suppress disease as well as when given on day -5. This is possibly due to the timing of 
the delivery of the Ac-PLP-BPI-NH2-2-NP, which is too close to the time of disease 
onset (day ~10). In this case, the peptide may not be completely released by the onset of 
the disease. In vitro release studies suggest that it takes approximately eight days for the 
peptide to completely release for the mice to receive the full dose. Therefore, for the 
peptide to be fully effective, Ac-PLP-BPI-NH2-2-NP would need to be administered 
anywhere between day -5 and day 4. It is also plausible that the difference in the efficacy 
of the two treatments was due to the production of regulatory and suppressor cells that 
shift the balance of the immune system to a non-immunogenic phenotype in the group 
treated on day -5. Cytokine studies need to be done in the future to confirm this proposal.  
Most of the initial cases of MS are characterized as relapsing-remitting.25 To test 
for the ability to suppress relapse after remission, Ac-PLP-BPI-NH2-2-NP was 
administered on day 30. We observed that while the group initially showed clinical signs 
of improvement, the treatment was not able to fully suppress relapse. Because MS is an 
autoimmune disease that generally involves multiple epitopes from different myelin 
sheath proteins, it is possible that the peptide is suppressing a subpopulation of T cells 
that are responsible for the recognition of PLP; however, the MOG- and MBP-specific T 
cells may be responsible for the relapse in disease.2,26 The reason a relapse was not 
observed in the Ac-PLP-BPI-NH2-2-NP (day -5) group was possibly because the peptide 
completely suppressed any immunogenic T cells in the early stage, and this resulted in a 
shift in the immune balance towards a regulatory response before any epitope spreading 
occurred.26 
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Th17 is thought to play a large role in the pathogenesis of both EAE and MS.27 
Through cytokine studies, it was revealed that IL-6, a proinflammatory marker that is a 
precursor for Th17 production, was significantly lower in both Ac-PLP-BPI-NH2-2 and 
Ac-PLP-BPI-NH2-2-NP treatment groups.27 Furthermore, IL-6 is important in the 
breakdown of the blood brain barrier (BBB), a hallmark of MS and EAE.28 Our previous 
work had shown that Ac-PLP-BPI-NH2-2 prevented the destruction of the BBB 
(unpublished data). The lower IL-6 production by the Ac-PLP-BPI-NH2-2-NP group 
compared to the Ac-PLP-BPI-NH2-2 group suggested that continual exposure to the 
peptide dose may be better at suppressing Th17 production. It could also be that the 
higher initial dose followed by a more sustained release provided by the colloidal gel 
formulation might be a more optimal way to deliver this peptide. Lower levels of IL-17 
by both treatments compared to blank-NP on day 55 corroborate the IL-6 findings, 
suggesting that suppression of Th17 production was the major mechanism of the peptide. 
The other inflammatory marker, IFNγ, was also significantly lower in the treated groups 
than in the blank-NP group. Just as in IL-6, IFNγ was significantly lower in the 
Ac-PLP-BPI-NH2-2-NP group compared to the mice group treated with bolus injections 
of Ac-PLP-BPI-NH2-2, suggesting that delivering the peptide using a colloidal gel 
formulation is more advantageous at suppressing the Th1 immunogenic response. 
Th2 cells generally function as suppressor cells and usually develop in the 
presence of IL-4.29 IL-4 production was not significantly different in the treatment groups 
compared to the negative control. This suggests that Th2 involvement, especially during 
the peak of the relapse (day 55), may not be as important as Th17. IL-5, also considered 
to be a Th2 marker, was significantly lower in the group treated with 
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Ac-PLP-BPI-NH2-2-NP compared to the controls. IL-2 levels in the Ac-PLP-BPI-NH2-2 
treatment group were also significantly higher. These results suggested that, although the 
peptide used for treatment is the same, the dosing schedule and dose availability play 
vital roles in developing an immunotolerant state.  
 
3.5 CONCLUSIONS 
In conclusion, a one-time injection given in a vaccine-like manner with the 
colloidal gel formulation loaded with Ac-PLP-BPI-NH2-2 suppressed EAE as well as the 
three-times injection of the positive control, Ac-PLP-BPI-NH2-2. Even though treatment 
with Ac-PLP-BPI-NH2-2-NP on day 4 could suppress EAE, the timing of the dose was 
found to be an important factor in suppressing disease. Ac-PLP-BPI-NH2-2-NP was also 
found to suppress disease by downregulating production of IL-6 and IL-17, cytokines 
associated with Th17 production. Future studies using Ac-PLP-BPI-NH2-2-NP will aim 
to further elucidate its mechanism of action. The effect of epitope spreading will be 
studied by co-administering other immunodominant epitopes, such as MOG-BPI.26 
Finally, a colloidal gel was found to be an effective way of delivering 
Ac-PLP-BPI-NH2-2 in a controlled-release manner without the loss of peptide during 
formulation. 
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CHAPTER 4 
The effects of bifunctional peptide inhibitors in suppressing rheumatoid arthritis in 
an animal model 
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4.1 INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease that causes pain, stiffness, 
chronic inflammation, and deformity due to cartilage, bone, and ligament destruction in 
the joints.1 Although the etiology of RA is not fully understood, it has been suggested 
that the cause of the disease is the attack of the host joints by immune cells along with the 
generation of lymphocytes that release inflammatory cytokines such as tumor necrosis 
factor (TNF)-α, interferon (IFN)γ, interleukin (IL)-1, and IL-6.2-5 T helper-1 (Th1) cells 
infiltrate the synovium where they release proinflammatory cytokines and chemokines 
that promote macrophage and neutrophil infiltration and activation.1,4,6 Th17, a subset of 
T-helper (Th) cells, have also been implicated in autoimmune diseases such as 
rheumatoid arthritis.3,7 Another possible cause is that the body fails to activate regulatory 
T cells (T-reg); thus, enhancing the functions of T-reg may be one therapeutic strategy to 
suppress RA and other autoimmune diseases.8-12 
Because there is no known cure for RA, current treatments are aimed at 
decreasing joint inflammation and pain, maximizing joint function, and preventing joint 
destruction. RA medications can be divided into “first-line” and “second-line” drugs. The 
first-line drugs include various non-steroidal anti-inflammatory drugs (NSAIDs) (i.e., 
aspirin, naproxen, ibuprofen, etodolac, and celecoxib) and corticosteroids.13,14 NSAIDs 
normally act quickly to ameliorate pain and decrease tissue inflammation and swelling; 
however, they have side effects that can cause upset stomach, abdominal pain, ulcers, and 
GI bleeding.15 
The second-line drugs are disease-modifying antirheumatic drugs (DMARDs), 
which include immunosuppressive drugs such as methotrexate (Rheumatrex®, Trexall™), 
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azathioprine (Imuran®), cyclophosphamide (Cytoxan®), Chlorambucil (Leukeran®), and 
cyclosporine (Sandimmune®). These slower acting drugs promote RA remission and 
prevent progressive joint destruction (i.e., cartilage, bone, and adjacent soft tissues). 
These drugs may take up to a few months to become effective. With the exception of 
methotrexate, immunosuppressive drugs are generally reserved for patients with very 
aggressive disease or serious rheumatoid inflammation complications, such as 
vasculitis.13 These can have side effects that suppress bone marrow function, causing 
anemia, decreased white blood cell and platelet counts, and increased risk of infection 
and bleeding.  
Newer second-line drugs, called biologic response modifiers (i.e., Enbrel® 
(etanercept), Remicade® (infliximab), Humira® (adalimumab), Rituxan® (rituximab), and 
Orencia® (abatacept)), are more specific and have a quicker onset of action to prevent 
progressive joint destruction in RA. For example, golimumab, etanercept, infliximab, and 
adalimumab act to lower TNFα levels in the systemic circulation, whereas Orencia® 
blocks T-cell activation.13,14,16,17 Their use is recommended after initial second-line 
medications have been shown to be ineffective, and they are often more effective in 
combination with DMARDs.13,14 
Although the current biologic response modifiers have been effective in treating 
patients, they can suppress the general immune system and ultimately increase the risk of 
infections. Therefore, there is a need to develop a new immune modulator that can 
selectively suppress the activity of a sub-population of the immune cells that cause joint 
damage in RA and that decrease the likelihood of a totally immune-compromised host. In 
this study, a novel type of bifunctional peptide inhibitor (BPI) molecule called CII-BPI 
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(i.e., CII-BPI-1, CII-BPI-2, and CII-BPI-3; Table 1) that selectively suppresses the 
activation of a subpopulation of T cells that respond to collagen II antigen was developed. 
These molecules are composed of antigenic peptides from collagen II (i.e., CII256-270, and 
CII1237-1249, CII707-721) linked via a spacer to a cell adhesion peptide called LABL. The 
LABL peptide is derived from the I-domain of αL-integrin (CD11a237-246), which binds to 
ICAM-1. The hypothesis of how BPI molecules suppress RA is that CII-BPI binds 
simultaneously to MHC-II and ICAM-1 on the surface of antigen-presenting cells (APC) 
and alters the differentiation of naïve T cells to T-reg upon interaction of these APC with 
naïve T cells to halt the progression of the disease. At the molecular level, because BPI 
molecules bind simultaneously to MHC-II and ICAM-1, they may block the formation of 
the immunological synapse necessary for T-cell activation.18 The ability of CII-BPI 
molecules to suppress the progression of RA were evaluated and compared to those of the 
respective parent antigenic peptides from collagen II in the CIA mouse model. The effect 
of CII-BPI molecules in altering cytokine production was also determined. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
The DBA1BO-M male mice utilized in study-I were purchased from Taconic 
Farms (Germantown, NY). For study-II and -III, DBA/1J male mice were purchased 
from Jackson Laboratory (Bar Harbor, ME). All mice were housed under specific 
pathogen-free conditions at the animal facility at The University of Kansas approved by 
the Association for Assessment and Accreditation of Laboratory Animal Care. All 
 108 
Table 1. The sequences of peptides used in the present study 
CII Sequence Source Peptide Sequence 
CII256-270 CII-1 Ac-GEPGIAGFKGEQGPK-NH2 
CII256-270 CII-BPI-1 Ac-GEPGIAGFKGEQGPK-(AcpGAcpGAcp)2-
ITDGEATDSG-NH2 
CII1237-1249 CII-2 Ac-QYMRADEADSTLR-NH2 
CII1237-1249 CII-BPI-2 Ac-QYMRADEADSTLR-(AcpGAcpGAcp)2-
ITDGEATDSG-NH2 
CII707-721 CII-3 PPGANGNPGPAGPPG 
CII707-721 CII-BPI-3 Ac-PPGANGNPGPAGPPG-(AcpGAcpGAcp)2-
ITDGEATDSG-NH2 
Ac = Acetyl Group; Acp = !-aminocaproic acid; G = Glycine 
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experimental procedures using live mice were approved by the Institutional Animal Care 
and Use Committee at The University of Kansas.  
 
4.2.2 Peptide synthesis 
The peptides used in this study (Table 4.1) were synthesized using a solid phase 
peptide synthesizer (Pioneer; Perceptive Biosystems, Framingham, MA) on a 
polyethylene glycol-polystyrene resin (Applied Biosystems, Foster City, CA) with 9-
fluorenylmethyloxycarbonyl-protected amino acid chemistry. Cleavage of the peptides 
from the resin and removal of the protecting groups were carried out using trifluoroacetic 
acid in the presence of scavengers. The crude peptides were purified by reversed-phase 
high-performance liquid chromatography (HPLC) using a C18 column with a gradient of 
solvent A (94.9% H2O with 0.1% trifluoroacetic acid and 5% acetonitrile) and solvent B 
(100% acetonitrile). The purity of the peptide was analyzed by analytical HPLC using an 
analytical C18 column. The peptide identity was confirmed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. 
 
4.2.3 Induction of CIA and therapeutic study 
For study-I, a readily prepared chicken collagen/CFA emulsion, containing 1.0 
mg/ml of type II chicken collagen and 2.0 mg/ml of mycobacterium tuberculosis, was 
injected intradermally (Hooke Laboratories, Lawrence, MA). This was followed by an 
intradermal IFA emulsion injection, containing 1 mg/ml of chicken type-II collagen, on 
day 21. The mice were given intravenous (i.v.) injections of CII-1 and CII-BPI-1 peptides 
(100 nmol/injection) on days 17, 22, 25, and 28. 
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For study-II and -III, bovine type II collagen (CII, Elastin Products, Owensville, 
MO) was dissolved in 0.05 M acetic acid overnight at 4°C at a concentration of 6 mg/ml. 
CFA was prepared by addition of killed mycobacterium tuberculosis H37RA (Difco, 
Detroit, MI) to IFA (Difco) at a concentration of 8 mg/ml. The solution of CII (6 mg/ml) 
was emulsified in an equal volume of CFA. Six- to eight-week-old DBA/1J mice were 
immunized with 100 µl of emulsion containing 300 µg CII and 400 µg mycobacteria 
injected intradermally at the tail base. After 21 days, all mice received a booster dose of 
100 µl of emulsion containing 300 µg CII injected intradermally at the tail base. For 
study-II, the mice received i.v. injections of CII-BPI-1, CII-BPI-2, CII-1, and CII-2 (100 
nmol/injection) on days 19, 22, and 25. For study-III, the same disease induction protocol 
was followed, with the mice receiving i.v. injections of CII-BPI-3 and CII-3 peptides 
(100 nmol/injection) on days 19, 22, and 25. In another group, mice were injected with 
5 mg/kg in 100 µl of MTX-cIBR for 10 days from day 19. MTX-cIBR is a conjugate of 
methotrexate and a cIBR adhesion peptide derived from ICAM-1. 
Initially, disease progression was evaluated by using a clinical scoring scale for 
each paw ranging from 0 to 4 as follows: 0–no clinical symptoms, 1–paws with swelling 
of finger joints or redness; 2–paws with mild swelling of wrist or ankle joints; 3–paws 
with severe swelling of entire paw; 4–paws with deformity or ankylosis. Disease 
progression was also evaluated throughout the study by measuring the increase in paw 
swelling of the fore limbs as well as hind limbs. 
 
4.2.4 Determination of IL-6 levels in serum in vivo 
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Cytokine production in the peptide-treated and untreated mice was measured by 
obtaining blood samples on days 31 and 44 from study-I without sacrificing the mice. 
Blood samples were allowed to clot overnight at 4 °C before centrifuging at 5,000 rpm 
for 10 minutes the next day. Serum was collected and stored at -80 °C until analysis. 
Serum IL-6 analysis was performed using a fully quantitative ELISA-based Q-PlexTM 
Mouse Cytokine-Screen (Quansys Biosciences, Logan, UT). Serum IL-1, IL-4, IL-5, IL-
10, IL-17, TNFα, and IFNγ were below the detection limit. 
 
4.2.5 Histopathology of the joints 
Development of CIA in DBA mice was also assessed histologically. In study-II, 
both hind limbs were removed 30 days after the second immunization and fixed in 
formalin prior to analysis. Arthritic changes and joint damage were individually scored 
(articular cartilage damage, pannus formation, synovial membrane thickening, synovial 
capsule thickening, inflammatory cell infiltrate) and totaled as: 0, no lesions; 1, mild 
changes; 2, moderate changes; 3 and 4, severe changes. The histopathology evaluation 
was done by Dr. Stan Kosanke at the University of Oklahoma Health Sciences Center. 
 
4.2.6 Statistical analysis 
Statistical differences among the groups in clinical scoring, volume displacement, 
serum IL-6 levels, and histopathological score were determined by one-way analysis of 
variance followed by Fisher’s least significant difference. All analyses were performed 
using StatView (SAS Institute, Cary, NC). 
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4.3 RESULTS 
4.3.1 Suppression of CIA by CII-BPI 
In study-I, DBA1BO-M male mice were used and disease was stimulated using 
chicken collagen in CFA. DBA1BO-M mice developed more severe clinical arthritis than 
the DBA/1J mice utilized in study-II and -III. Two different injection schedules (3 and 4 
injections) were carried out to compare the efficacy of CII-BPI-1 and CII-1 peptides. The 
clinical scores indicated that both CII-1 and CII-BPI-1 peptides were significantly better 
in suppressing the arthritis compared to PBS (p < 0.0001, through days 28-44)(Fig. 4.1A). 
Using clinical scores, it was difficult to differentiate the efficacy of CII-1 and CII-BPI-1; 
however, the differences were clear when comparing paw swelling measurements 
because this method is more objective and quantitative.  
According to the percent changes in paw swelling of all four limbs (Fig. 4.1B), it 
was clear that 3 and 4 injections of CII-BPI-1 and 4 injections of CII-1 peptides were 
significantly more effective than PBS and 3 injections of CII-1 peptide (p < 0.001, 
through days 34–44). It was difficult to differentiate the efficacy of 3 and 4 injections of 
CII-BPI-1 peptide. However, 3 injections of CII-BPI-1 were significantly better than 3 
injections of CII-1 peptide (p < 0.001, through days 34–44), suggesting that CII-BPI-1 is 
more potent than CII-1 peptide. Evaluating the changes in paw volume of both hind limbs 
only (Fig. 4.1C), there was a trend to suggest that 4 injections of CII-BPI-1 were more 
effective than 3 injections of CII-BPI-1 (p-value of 0.0575, through days 34–44) and 4 
injections of CII-1 peptide (p-value of 0.0893, through days 34–44). In this animal model, 
three injections of CII-1 peptide did not show any efficacy in suppressing the changes in 
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Figure 4.1 In vivo activity of the CII-1 and CII-BPI-1 peptides in the mouse CIA 
model with varying injections. In study-I, DBA1BO male mice were immunized with 
CII/CFA intradermally and given a booster dose on day 21. The mice were then given 
four i.v. injections of peptides (100 nmol/injection) on days 17, 22, 25, and 28 or only 
three injections on days 17, 22, and 25. The disease progression was observed by (A) 
clinical scoring, (B) monitoring the changes in the volume of all four paws, or (C) by 
measuring just the hind paws. The results are expressed as the mean ± standard error 
(n = 7–9). Figure 4.1A: All peptides groups are significantly better than PBS (p < 
0.0001, through days 28–44). 
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Figure 4.1B There were significant differences in the volume displaced by all four 
paws between four injections of CII-BPI-1 and PBS (p < 0.0001, through days 34–44), 
and three injections of CII-1 (p < 0.0001, through days 34–44). Three injections of 
CII-BPI-1 were significantly better than PBS (p < 0.001, through days 34–44) and 
three injections of CII-1 (p < 0.001, through days 34–44). 
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Figure 4.1C There were significant differences in the volume displaced by the hind 
paws between four injections of CII-BPI-1 and PBS (p < 0.0001, through days 34–44), 
and three injections of CII-1 (p < 0.0001, through days 34–44). The p-value for the 
difference between four injections of CII-BPI-1 and four injections of CII-1 is 0.0893. 
A p-value of 0.0575 suggests that four injections of CII-BPI-1 are better than three 
injections of CII-BPI-1. 
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paw volume. These results suggested that CII-BPI-1 was more potent than CII-1 peptide 
and that the activity of these peptides was dose-dependent.  
In study-II, disease was induced using bovine collagen, and the efficacies of CII-
BPI-1 and CII-BPI-2 were compared to those of their respective antigenic peptides, CII-1 
and CII-2, in suppressing CIA (Fig. 4.2). The changes in paw volume suggested that CII-
BPI-1 had the best activity in suppressing arthritis in mice compared to the other peptides, 
as well as PBS (Fig. 4.2). Although there was a trend indicating that CII-BPI-2 was better 
than CII-2 peptide, the difference was not statistically significant. It was clear that CII-
BPI-1 had better efficacy than CII-BPI-2 and CII-2 peptide (p < 0.05, through days 40–
44) and there was a trend to suggest that CII-2 could aggravate the disease compared to 
PBS. 
In study-III, four groups of DBA/1J male mice were induced with disease. Then, 
two groups were injected three times intravenously with 100 nmol/injection of CII-BPI-3 
and CII-3 peptides on days 19, 22, and 25; one group was injected with PBS. Another 
group was treated with MTX-cIBR with a daily dosing schedule of 5 mg/kg starting from 
day 19 for 10 consecutive days. The changes in paw volume due to swelling were 
significantly lower in CII-BPI-3-treated mice than in those treated with PBS (Fig. 4.3; p 
< 0.05 from days 40 to 44). There was significant suppression of arthritis in CII-3 
peptide-treated mice compared to the PBS-treated control group (p < 0.05 from days 40 
to 44). CII-BPI-3 peptide had a better CIA suppressive activity than CII-3 peptide (p < 
0.01, through days 40–44), suggesting that forming BPI-type molecules improved the 
biological activity of the peptide. The positive control treatment, MTX-cIBR (5 mg/kg), 
 117 
  
0 
5 
10 
15 
20 
25 
30 
35 
40 
21 24 27 30 33 36 39 42 45 
%
 T
ot
al
 P
aw
 V
ol
um
e 
D
is
pl
ac
ed
 ±
 S
E
 
Time (Days) 
PBS 
CII-1 
CII-2 
CII-BPI-1 
CII-BPI-2 
Figure 4.2 Comparing the in vivo efficacies of CII-BPI-1 and CII-BPI-2 with those of 
their respective antigenic derivatives, CII-1 and CII-2, in the mouse CIA model. The 
negative control was mice treated with PBS. In the second study, mice immunized 
with CII/CFA received i.v. injections of the shown peptides (100 nmol/injection) on 
days 19, 22, and 25. There were significant differences in the changes in paw volume 
between CII-BPI-1- and PBS-treated (p < 0.0001, through days 40–44) and between 
CII-BPI-2- and PBS-treated groups (p < 0.05, through days 40–44). There was also a 
significant difference in mice treated with CII-1 and PBS (p < 0.0005, through days 
40–44). In addition, a significant difference between the CII-BPI-1 and CII-BPI-2 
groups was observed (p < 0.05, through days 40–44). The results are expressed as the 
mean ± standard error (n = 7–9).  
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Figure 4.3 The efficacies of CII-BPI-3, CII-3 and MTX-cIBR in suppressing 
rheumatoid arthritis were compared to those of PBS using the CIA mouse model. 
DBA/1J mice were immunized intradermally at the tail base with CII/CFA on day 0 
followed by a booster dose at day 21. In study-III, three groups of mice were injected 
with 100 nmol of CII-BPI-3, CII-3, and PBS intravenously on days 19, 22, and 25. In 
another group, mice were injected with 5 mg/kg in 100 uL of MTX-cIBR for 10 days 
from day 19. The changes in paw volume were measured daily. There were significant 
differences in paw volume between CII-BPI-3- and PBS-treated and between CII-3- 
and PBS-treated groups (p < 0.01, through days 40–44). There was a significant 
difference in the changes in paw volume in mice treated with CII-BPI-3 and CII-3 (p < 
0.01, through days 40–44). The results are expressed as the mean ± standard error (n = 
7–9).  
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suppressed arthritis better than PBS (p < 0.01, through days 40–44) and with almost the 
same potency as that of the CII-BPI-3 peptide (p > 0.10, through days 40–44). 
 
4.3.2 IL-6 serum levels in DBA mice in vivo 
To determine the effect of the CII-BPI treatment in study-I on cytokine levels 
(Fig. 4.4), the levels of different cytokines in the serum were quantified using ELISA on 
day 31 at around the disease peak and on day 44 when the arthritis swelling was at the 
plateau region. Unfortunately, the levels for IL-1, IL-4, IL-5, IL-10, IL-17, TNFα, and 
IFNγ were below the detection limit in serum and only IL-6 could be detected in the 
serum. On day 31, the IL-6 levels were significantly lower in mice injected 3 times with 
CII-BPI-1 than in those treated with PBS (p < 0.0001) and CII-1 (p < 0.0001)(Fig. 4.4A). 
Furthermore, the CII-1-treated group had higher serum IL-6 levels than the PBS group (p 
< 0.0001). Once the arthritic swelling reached a plateau on day 44 (Fig. 4.4B), the serum 
IL-6 concentration of the CII-1 group significantly decreased compared to the PBS-
treated group (p < 0.0001), and no significant difference was observed when compared to 
the group receiving CII-BPI-1. These results suggested that CII-BPI-1 and CII-1 might 
have had different mechanisms of suppressing arthritis. 
In the groups injected four times with treatment peptides, the serum level of IL-6 
in the CII-1 group was nearly three times higher than in the PBS-treated group at the peak 
of the disease on day 31 (p < 0.0001)(Fig. 4.4C). No significant difference between IL-6 
concentrations of CII-BPI-1 and PBS on day 31 was observed. Analysis of the mouse 
cytokine levels at the end of the study (day 44) showed that IL-6 levels were lower in 
both the CII-1 and CII-BPI-1 groups when compared to the PBS group (p < 0.0001). As 
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Figure 4.4 The serum cytokine levels of IL-6 of mice treated with PBS, CII-1 and CII-
BPI-1 on days 31 and 44. Figure 4.4A: Mice treated with three injections of CII-BPI-
1 had significantly lower levels of IL-6 in the serum than those injected with PBS (*, p 
< 0.0001) and three injections of CII-1 (#, p < 0.0001). Serum IL-6 levels were 
significantly higher in the mouse group treated with CII-1 than in the PBS-treated 
group (@, p < 0.0001).   
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Figure 4.4B Serum levels of the cytokine IL-6 were significantly lower on day 44 
after three-times injections of CII-1 (*, p < 0.0001) and CII-BPI-1 (*, p < 0.0001) 
compared to PBS. A significant difference between IL-6 levels of CII-1 and CII-BPI-1 
on day 44 was not observed.   
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Figure 4.4C Comparison of serum IL-6 levels of mice treated with four injections of 
PBS, CII-1, and CII-BPI-1 on days 31 and 44. Serum IL-6 levels were significantly 
higher in the CII-1 group compared to PBS (@, p < 0.0001) and CII-BPI-1 (*, p < 
0.0001). Significant differences between IL-6 levels of CII-BPI-1 and PBS were not 
observed. On day 44, serum IL-6 levels were significantly higher in the PBS-treated 
group compared to CII-1 (*, p < 0.0001) and CII-BPI-1 (*, p < 0.0001). No significant 
difference in IL-6 levels was observed between CII-1 and CII-BPI-1 treatments on day 
44. 
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with day 31, the results of the IL-6 levels obtained from mouse serum on day 44 suggest 
that tethering an adhesion molecule to the antigenic peptide in CII-BPI-1 may induce a 
different immune response than that of CII-1 peptide. 
 
 4.3.3 Histopathological analysis 
To evaluate the effect of CII-BPI molecules in suppressing the progress of 
arthritis in the joints, the histopathology of the joints of three representative animals from 
study-II were examined for cartilage erosion and cell infiltration in the joint space. For 
the untreated arthritic mice, the knee joints had moderate evidence of articular cartilage 
damage with pannus formation (Fig. 4.5A). The synovial membrane and capsule were 
both markedly thickened as a result of pannus formation and had inflammatory cell 
infiltration. The synovial linings were hyperplastic with sloughing of synoviocytes into 
the joint space. The inflammatory cellular infiltrate consisted of a mixture of mostly 
synovial macrophages, neutrophils, and lymphoplasmacytic cells. In the untreated 
arthritic group, the chronic inflammation destroyed the joint lining, including the 
cartilage and other nearby supporting structures, such as bone (Fig. 4.5B). The formation 
of pannus is a result of overgrowth of the synoviocytes and the observed accumulation of 
inflammatory cells that led to deformed cartilage and bone, which agreed with the 
observed clinical scores. 
 For mice treated with CII-1 peptide, four out of six knee joints appeared normal 
(Fig. 4.5C) and the two remaining joints had very mild evidence of synovial membrane 
thickening with pannus formation, which falls within normal limits. Minimal evidence of 
chronic inflammation and articular cartilage damage were observed in the mice group 
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Figure 4.5 Representative images of histological analysis of knee joints of peptide-
treated and PBS-treated mice. Figures 4.5A and 4.5B are images of the joints of PBS-
treated mice with articular cartilage damage as well as a collection of cellular exudates 
within the joint spaces. Figure 4.5C is the image of mouse joint treated with CII-1 
peptide, which appears essentially normal. Figure 4.5D is the image of the joint of a 
mouse treated with CII-BPI-1 showing minimal inflammation. J=joint space 
M=synovial membrane P=pannus formation A=articular cartilage. 
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treated with CII-BPI-1 (Fig. 4.5D). Two of the six knee joints from the mice treated with 
CII-BPI-1 had very mild evidence of synovial membrane thickening. Mice treated with 
CII-1 and CII-BPI-1 had a lower incidence of inflammation and cell infiltration into the 
joint space as well as cartilage damage. Overall, mice treated with CII-1 and CII-BPI-1 
peptides had significantly lower joint histopathological scores than the PBS-treated group 
(p < 0.0001)(Fig. 4.6). The CII-1-treated and CII-BPI-1-treated mice had significantly 
lower cartilage erosion and inflammatory infiltrates in the joint space compared to those 
treated with PBS. 
 
4.4 DISCUSSION  
BPI molecules were developed by conjugating antigenic peptides to cell adhesion 
peptides (i.e., LABL peptide) derived from the I-domain of LFA-1 that binds to ICAM-
1.19 The hypothesis is that BPI molecules target and bind to the molecular components 
(Signal-1 and Signal-2) of the immunological synapse; thus, they inhibit the translocation 
of Signal-1 and Signal-2 for the final formation of the immunological synapse at the 
interface of T cell and antigen-presenting cell.18,20 The current studies showed a proof-of-
concept that BPI molecules such CII-BPI-1 and CII-BPI-3 have greater efficacies to 
suppress arthritis in CIA mice than their respective parent antigenic peptides (CII-1 and 
CII-3) and PBS (Fig. 4.7). It was also found that neither CII-BPI-2 nor CII-2 peptides 
were effective in preventing the progress of arthritis, suggesting that the sequence of the 
antigen was not appropriate for inducing tolerance in this model. This finding was 
consistent with our previous results in which another type of BPI molecule (proteolipid 
protein (PLP)-BPI derivatives) can suppress experimental autoimmune encephalomyelitis 
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Figure 4.6 Comparison of the mean scores of joint histopathology of normal untreated 
mice and diseased mice treated with PBS, CII-BPI-1, and CII-1 peptides in the mouse 
CIA model. There were significant differences between groups treated with PBS and 
CII-BPI-1 (p < 0.0001) and CII-1 (p < 0.0001). 
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Figure 4.7 Representative images of the hind paws of mice treated with either PBS 
(Figure 4.7A) or CII-BPI-1 (Figure 4.7B). 
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(EAE) in the mouse model (a model for multiple sclerosis) more effectively than the 
parent PLP antigenic peptide.21-23 In addition, GAD-BPI peptide could also suppress 
type-1 diabetes (T1D) in non-obese diabetic (NOD) mice.18 These results suggested that 
BPI molecules have proven effective in suppressing three different autoimmune diseases 
(RA, MS, and T1D). Because BPI molecules are usually more effective than the parent 
antigenic peptides in suppressing autoimmune disease in animal models, this suggested 
that the cell adhesion peptide (i.e., LABL portion) in BPI has an important role in the in 
vivo activities of BPI molecules. 
Although the mechanisms of action of the CII-BPI peptide remain to be fully 
elucidated, our previous work with PLP-BPI in EAE mouse model showed that the PLP-
BPI treatment increased TGF-β and IL-10 production, suggesting the involvement of T-
reg.18 Both PLP-BPI and GAD-BPI enhanced the production of IL-4, indicating the 
involvement of Th2 differentiation and proliferation. The PLP-BPI-treated animals had 
lower IL-17 than those treated with PBS, indicating the suppression of Th17 
proliferation.21 Researchers have recently confirmed the importance of the IL-17-
producing Th17 in CIA.24 In two separate experiments, the absence of Th17 lymphocytes 
in mice deficient in IL-17 and the administration of anti-IL-17 antibodies were shown to 
significantly reduce the severity of CIA.25,26 Altered peptide ligands (APL) derived from 
collagen II also suppressed arthritis by the expansion of T-reg and lowering of Th1 and 
Th17.27,28 IL-17 has been reported to activate osteoclasts and induce the production of 
various cytokines (IL-6, IL-8, IL-1, and TNFα) by macrophages, monocytes, and 
synoviocytes.11,29,30 
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Studies support the importance of IL-17, showing that IL-17-deficient mice could 
mitigate CIA development by curbing the activation of autoantigen-specific T cells and B 
cells in the sensitization phase of CIA.31 Although IL-23 is important in the 
differentiation of Th17, cytokines such as IL-6 and IL-21 have been directly implicated in 
the induction of Th17.30,32,33 IL-6 has been shown to induce Th17 differentiation in both 
humans and mice. A study by Kelchtermans et al. showed that a transfer of T-reg 
significantly improved CIA and also lowered TNFα as well as IL-6 levels in mouse 
sera.11 The decreased levels of mouse IL-6 cytokine in mouse sera that was observed on 
day 44 in the current study would suggest that CII-1 and CII-BPI-1 induced similar 
mechanisms to suppress CIA, by regulating the immune cells responsible for arthritis.8 In 
the EAE mouse model, it was also shown that a deficiency of IL-6 shifted the immune 
response away from an immunogenic role to a protective one.34 Given our results, a 
similar mechanism is possible when CIA mice are treated with CII-BPI.  
It is interesting to note that even though our results show that CII256-270 antigenic 
peptide eventually lowered IL-6 levels, IL-6 is higher than in the control group during the 
peak of the disease. In contrast, CII256-270-BPI (CII-BPI-1) had significantly lower levels 
of the inflammatory IL-6 cytokine in the thrice-injected mice and also significantly lower 
IL-6 levels at the peak of disease (day 31 – 4x injected) when compared to CII-1. The 
lower levels of IL-6 for CII-BPI-1 also corresponded well with our clinical paw swelling 
data. The cytokine results in our study suggested that the CII-BPI-1 peptide suppressed 
disease by decreasing IL-6 response. This can, in turn, suppress the downstream Th17 
proliferation and perhaps enable a shift in the balance toward T-reg proliferation. 
Similarly, an anti-IL-6 receptor antibody, called tocilizumab, has been used to treat 
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rheumatoid arthritis. We also propose that, by decreasing the serum levels of IL-6, we are 
also inhibiting osteoclastogenesis.11 In arthritis, osteoclasts are present in the inflamed 
synovium and greatly contribute to the destruction of bone. Histopathology of the mice 
treated with CII-BPI-1 confirmed the absence of osteoclasts.  
The extracellular matrix of cartilage contains mainly type II (CII) collagen. CII, 
like myelin basic protein, can elicit tissue-specific autoimmune disease.35-37 Currently, 
there are peptides that have been investigated for suppressing a subpopulation of T cells 
that can induce immunotolerance. These include peptide sequences that are derived from 
CII and have been shown to hinder the progression of CIA: CII256-270, CII707-721, or 
CII1237-1249.38,39 The selection of CII peptides in this study was based on previous studies 
showing that certain epitopes such as CII256-270 can bind to I-Aq MHC class II 
molecules.37,40 Previous experiments with CII256-270 have also shown that this peptide 
sequence can inhibit the progression of CIA.37 It has been suggested that CII260-267 is the 
immunodominant core.37,41 As a result of crystallographic analysis and alanine scanning, 
in rheumatoid arthritis, 267Q and 270K have been determined to be T-cell receptor 
(TCR) contact residues, while 263F and 266E are mainly responsible for binding with 
HLA-DR.42-44 Another major immunodominant epitope (CII707-721, CII-3) that we studied 
has previously been found to elicit a significant proliferative T-cell response.38 This 
peptide contains a combination of two overlapping core sequences of CII704-712 and CII710-
718.38 CII707-721 acetylated at the N-terminus and amidated at the C-terminus was shown to 
further enhance T cell proliferation. It has been observed that IFN-γ release correlates 
well with the proliferative responses induced by CII707-721.38 CII1237-1249 (CII-2) peptide 
was selected based on its ability to selectively bind to the RA-associated DR4 MHC 
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molecule.45-47 Because CII1237-1249 and CII707-721 have not been studied as extensively as 
CII256-270, their potential mechanisms have not been clearly elucidated. The susceptibility 
of mice to CIA is confined mostly to MHC type I-Aq.40  
These and other peptide molecules have been developed for treating CIA. As was 
reported here, small molecules that can block LFA-1/ICAM-1 interaction (LABL) can be 
attached to CII peptides and may facilitate a more specific suppression of T-cell 
activation. Here, it may be expected that the CII-BPI peptide will selectively block the 
activation of a subpopulation of T cells that recognizes the collagen peptide-MHC-II 
complex without eliminating the ability of the host to activate subpopulations of T cells 
that could fight pathogenic infections.  
 
4.5 CONCLUSIONS 
In conclusion, CII-BPI-1 and CII-BPI-3 can suppress CIA more effectively than 
CII antigens alone. Tethering of the LABL adhesion peptide to the CII peptide better 
suppressed CIA by perhaps shifting the immune balance from a pro-inflammatory to a 
regulatory response. This was supported by an observed deficiency in levels of mouse IL-
6 cytokine in mouse sera. To better elucidate the mechanism of the BPI peptide, 
splenocytes will be isolated to study other cytokine markers in the future. The effect of 
CII-BPI in altering immunological synapse formation will also be evaluated. Furthermore, 
optimization of the dose, dosing schedule, and utilization of a different route of delivery 
may yield better suppression of CIA. 
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CHAPTER 5 
Summary, conclusions, and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
5.1 SUMMARY AND CONCLUSIONS 
 The objective of the current work was to explore the possibility of delivering 
macromolecules (e.g., peptides and proteins) that are conjugated to functional peptides to 
antigen presenting cells (APC) for the suppression of autoimmune diseases in the mouse 
model. Peptides and proteins have been used as carriers to target and deliver molecules to 
sites of action. Whereas over 200 protein drugs are currently on the market, a small 
fraction of those drugs are conjugated products.1 Conjugating a drug to a macromolecule 
offers the advantage of being able deliver drug to a specific cell surface antigen with high 
affinity, thereby reducing any associated toxicity and increasing efficacy. Furthermore, 
conjugating peptides and proteins that have dual activities to modulate two or more 
receptors have shown promising results in animal models of autoimmune diseases.2 
Peptides and proteins (LABL and I-domain, respectively) derived from the alpha subunit 
of leukocyte function associated antigen-1 (LFA-1) bind to the first domain (D1) of 
intercellular adhesion molecule-1 (ICAM-1), an adhesion molecule that is normally 
upregulated during inflammatory processes.3-5 A bifunctional peptide inhibitor (BPI) 
molecule called GAD-BPI is a conjugate between an antigenic peptide (GAD) and an 
LABL peptide. GAD-BPI could simultaneously bind to MHC-II and ICAM-1 to co-
localize these two receptors on the surface of B cells from non-obese diabetic (NOD) 
mouse.6 The proposed mechanism is that colocalizing these two receptors with the 
bifunctional peptide inhibitors (BPI) prevents the formation of the immunological 
synapse during the interaction of antigen presenting cells (APC) and T cells to alter T cell 
differentiation and proliferation from effector T cells to regulatory T cells (T-reg).7  
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 In the first part of this work, we developed an I-domain antigen conjugate (IDAC) 
where I-domain was linked to multiple proteolipid protein (PLP) peptides for suppressing 
experimental autoimmune encephalomyelitis (EAE), an animal model for multiple 
sclerosis (MS). PLP139-151 was conjugated to the lysine residues of I-domain via a 
maleimide linker with an average of 2.5 PLP139-151 conjugations per protein molecule. 
Analysis of the secondary structure suggested that there was no difference in the 
secondary structure between IDAC and the naked I-domain protein. The applicability of 
IDAC to suppress EAE was tested using two different compounds, IDAC-1 and IDAC-3. 
The antigenic peptides of IDAC-3 had both the N- and C-termini capped to protect from 
exopeptidases, whereas IDAC-1 did not. In mice treated with two intravenous injections 
of IDAC-1 or IDAC-3 (26 nmol/injection), the onset and suppression of disease was 
inhibited more significantly in IDAC-3, suggesting that capping the ends of the peptide 
may increase its resistance to exopeptidases and therefore increasing its in vivo half-life. 
These studies were also the first to show that IDAC-3 could suppress the relapse of EAE 
when delivered in a vaccine-like manner. Cytokine studies suggested lower levels of IL-
17 production, and higher levels of IL-10 in the IDAC-3-treated group, suggesting that 
IDAC-3 suppressed disease by shifting the immune balance away from Th17-mediated 
pathology by increasing involvement of T-reg cells.  
 In the third chapter, it was demonstrated that PLP conjugated to LABL (Ac-PLP-
BPI-NH2-2) could be formulated in a colloidal gel and administered once subcutaneously 
(s.c.) to suppress EAE. We showed that Ac-PLP-BPI-NH2-2 could suppress EAE when 
injected s.c. three times in solution in a vaccine-like manner prior to the induction of 
disease. The rationale behind this work was to develop a one-time s.c. injection to mimic 
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the dosing schedule previously established in the Siahaan group.2,8 A one-time injection 
is ideal for achieving a higher degree of compliance not observed with multi-dose 
vaccinations. Ac-PLP-BPI-NH2-2 was formulated into colloidal gels containing 
oppositely charged Poly(D,L-lactic-co-glycolic acid) (PLGA) particles. Biocompatible 
polysaccharides provided negatively charged (alginate) and positively charged (chitosan) 
coating for the PLGA. In vitro results suggested that the entire dose of Ac-PLP-BPI-NH2-
2 was released by day 8. In vivo results indicated that a vaccine-like administration of Ac-
PLP-BPI-NH2-2 in a colloidal gel formulation could suppress EAE as well as the relapse. 
Cytokine studies suggested that the mechanism of suppression was due to the shift of the 
immune balance away from a Th17-mediated response. Colloidal gels have been shown 
in these studies to be an attractive option in delivering peptide drugs to release in a 
controlled-release manner without the loss of peptide during formulation. 
 Finally, we investigated the utility of bifunctional peptide inhibitors to target other 
autoimmune diseases such as collagen induced arthritis (CIA), an animal model of 
rheumatoid arthritis (RA). Here, we conjugated different antigenic peptide sequences 
derived from collagen type II (CII256-270, CII707-721, and CII1237-1249) to LABL. It was 
found that prophylactic treatment with CII256-270-BPI and CII707-721-BPI suppressed CIA 
more effectively than their parent compound. The fact that CII1237-1249-BPI did not 
suppress paw inflammation suggested that the sequence of antigen is important for 
inducing tolerance in this model. Furthermore, cytokine data suggested that CII linked to 
LABL shifted the immune balance from a proinflammatory to a regulatory response. 
These studies suggested that the BPI technology can be translated to other appropriate 
animal models. Because BPI molecules were shown to be more effective in suppressing 
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autoimmune disease in different animal models than the parent antigenic peptides, it can 
be concluded that the adhesion peptide (LABL) has an important role in the in vivo 
activities of BPI molecules. 
 
5.2 FUTURE DIRECTIONS 
5.2.1 Improving Delivery of IDAC to Suppress EAE 
Delivery of IDAC to the autoimmune animal model is still relatively new. 
Therefore, studies will need to be done to evaluate the effect of injections of IDAC-3 on 
the change or differentiation of immune cells. Furthermore, the effect of spreading the 
injections over a larger timespan as well as multiple injections (greater than 3) will be 
studied. In addition, the effect of increasing the dose while maintaining the same 
schedule of 2 injections will be evaluated. I-domain conjugated to a fluorophore (FITC) 
was observed to bind to and internalize after binding to LFA-1.9 In the future, studies will 
be carried out to elucidate the potential mechanisms of action of IDAC molecules on the 
surface of APCs. Because IDAC-3 is a mixture of PLP139-151, mutation studies will be 
performed to elucidate the active IDAC species. This will be done by mutating several 
lysine residues to cysteine (Cys-I-domain) for selective conjugation to PLP139-151 peptide. 
Finally, to address the issue of epitope spreading generally seen in MS, I-domain will be 
conjugated with other immunodominant epitopes, such as myelin oligodendrocyte 
glycoprotein (MOG), to create a multivalent I-domain protein. 
 
5.2.2 Optimizing Ac-PLP-BPI-NH2-2 Formulation in Colloidal Gel 
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 Colloidal gel formulated with Ac-PLP-BPI-NH2-2 was shown to suppress 
autoimmune EAE. In the future, colloidal gels will be tested to study the effects of 
slowing or increasing the rate of peptide release. One way to do so is to formulate a 
higher amount of PLGA coated with positively charged chitosan polysaccharide relative 
to PLGA-alginate as Ac-PLP-BPI-NH2-2 has a net negative charge. Another way to do 
this is to adjust the ratio of polymer:peptide. Depending on the day of treatment (day -5 
or day 4), a significant difference in the ability of colloidal gel formulated with Ac-PLP-
BPI-NH2-2 to suppress EAE was observed. The difference in efficacy may be due to the 
difference in the timing of the production of regulatory and suppressor cells. Therefore, 
time-dependent cytokine studies need to be done to confirm the effect of schedule of 
injection on the efficacy of IDAC molecules. 
 
5.2.3 Exploring the Mechanism of CIA Suppression 
 Future studies in this area should include further investigation of the ability of 
CII-BPI to suppress CIA. Splenocytes will be isolated to study other cytokine markers, 
such as IL-17 and IL-10. Studies should include the investigation of observing the 
alteration in immunological synapse formation. It is also important to optimize the dose, 
dosing schedule, and utilization of a different route of delivery to better suppress CIA. 
Administering CII-BPI in a vaccine-like manner would also be valuable in investigating 
the ability of the peptide to shift the balance of the immune response to a regulatory 
phenotype prior to the induction of disease. 
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